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Abstract
The	Gynecologic	Oncology	Committee	of	FIGO	in	2014	revised	the	staging	of	ovarian	
cancer,	 incorporating	 ovarian,	 fallopian	 tube,	 and	 peritoneal	 cancer	 into	 the	 same	
	system.	Most	of	these	malignancies	are	high-	grade	serous	carcinomas	(HGSC).	Stage	IC	
is	now	divided	into	three	categories:	IC1	(surgical	spill);	IC2	(capsule	ruptured	before	
surgery	or	tumor	on	ovarian	or	fallopian	tube	surface);	and	IC3	(malignant	cells	in	the	
ascites	or	peritoneal	washings).	The	updated	staging	includes	a	revision	of	Stage	IIIC	
based	 on	 spread	 to	 the	 retroperitoneal	 lymph	 nodes	 alone	without	 intraperitoneal	
	dissemination.	 This	 category	 is	 now	 subdivided	 into	 IIIA1(i)	 (metastasis	 ≤10	mm	 in	
greatest	dimension),	and	IIIA1(ii)	(metastasis	>10	mm	in	greatest	dimension).	Stage	IIIA2	
is	 now	 “microscopic	 extrapelvic	 peritoneal	 involvement	 with	 or	 without	 positive	
	retroperitoneal	lymph	node”	metastasis.	This	review	summarizes	the	genetics,	surgical	
management,	 chemotherapy,	 and	 targeted	 therapies	 for	 epithelial	 cancers,	 and	 the	
treatment	of	ovarian	germ	cell	and	stromal	malignancies.
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1  | INTRODUCTION
1.1 | Primary sites: ovarian, fallopian tube, and 
peritoneal cancer
In	2014,	the	Gynecologic	Oncology	Committee	of	FIGO	revised	the	
staging	to	 incorporate	ovarian,	 fallopian	tube,	and	peritoneal	cancer	
in	the	same	system.	Changing	the	staging	system	required	extensive	
international	consultation.	The	primary	site	(i.e.	ovary,	fallopian	tube,	
or	 peritoneum)	 is	 designated,	 where	 possible.	When	 it	 is	 not	 pos-
sible	 to	 clearly	delineate	 the	primary	 site,	 these	 should	be	 listed	 as	
“undesignated”.1,2
It	has	been	presumed	that	fallopian	tube	malignancies	were	rare.2 
However,	 histologic,	molecular,	 and	genetic	evidence	 shows	 that	 as	
many	as	80%	of	tumors	that	were	classified	as	high-	grade	serous	carci-
nomas	of	the	ovary	or	peritoneum	may	have	originated	in	the	fimbrial	
end	of	the	fallopian	tube.3–8	Therefore,	the	incidence	of	fallopian	tube	
cancers	may	have	been	substantially	underestimated.	These	new	data	
support	the	view	that	high-	grade	serous	ovarian,	fallopian	tube,	and	
peritoneal	cancers	should	be	considered	collectively,	and	that	the	con-
vention	of	designating	malignancies	as	having	an	ovarian	origin	should	
no	 longer	 be	 used,	 unless	 that	 is	 clearly	 the	 origination	 site.	 It	 has	
been	suggested	 that	extrauterine	 tumors	of	 serous	histology	arising	
in	 the	 ovary,	 fallopian	 tube,	 or	 peritoneum	might	 be	 described	 col-
lectively	as	 “Müllerian	carcinomas”1,2	or	 “pelvic	serous	carcinomas”.9 
The	latter	tumor	designation	is	controversial	because	some	peritoneal	
tumors	might	arise	 in	extrapelvic	peritoneum.	Therefore,	 the	 simple	
term	“serous	carcinoma”	is	preferred,	and	most	of	these	are	high-	grade	
serous	carcinomas	(HGSC).
Although	there	has	been	no	formal	staging	for	peritoneal	cancers,	
the	FIGO	staging	system	is	used	with	the	understanding	that	it	is	not	
possible	to	have	a	Stage	I	peritoneal	cancer.
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1.1.1 | Primary site
Ovarian	epithelial	 tumors	may	arise	within	endometriosis	or	cortical	
inclusions	of	Müllerian	epithelium,	 likely	a	 form	of	endosalpingiosis.	
These	include	low-	grade	endometrioid	carcinomas,	clear	cell	carcino-
mas,	borderline	and	low-	grade	serous	carcinomas,	and	mucinous	car-
cinomas.	These	tumors	are	thought	to	evolve	slowly	from	lower-	grade	
precursor	 conditions	 (endometriotic	 cysts,	 cystadenomas,	 etc.)	 and	
are	classified	as	type	I	tumors.5	Fallopian	tube	carcinomas	arise	in	the	
distal	fallopian	tube	and	the	majority	of	these	are	high-	grade	serous	
carcinomas.	These	are	thought	to	evolve	rapidly	from	more	obscure	
precursors	and	are	designated	as	type	II	tumors.5,6	This	 latter	group	
encompasses	high-	grade	endometrioid	carcinomas	and	carcinosarco-
mas.	All	of	these	high-	grade	carcinomas	are	nearly	always	associated	
with	mutations	in	the	TP53 gene.5
1.1.2 | Lymphatic and lymph node drainage
The	 lymphatic	drainage	of	 the	ovaries	and	fallopian	tubes	 is	via	 the	
utero-	ovarian,	infundibulopelvic,	and	round	ligament	pathways	and	an	
external	iliac	accessory	route	into	the	following	regional	lymph	nodes:	
external	 iliac,	 common	 iliac,	 hypogastric,	 lateral	 sacral,	 para-	aortic	
lymph	nodes	and,	occasionally,	to	the	inguinal	nodes.1,10–12 The peri-
toneal	surfaces	can	drain	through	the	diaphragmatic	lymphatics	and	
hence	to	the	major	venous	vessels	above	the	diaphragm.
1.1.3 | Other metastatic sites
The	peritoneum,	including	the	omentum	and	pelvic	and	abdominal	vis-
cera,	is	the	most	common	site	for	dissemination	of	ovarian	and	fallo-
pian	tube	cancers.	This	includes	the	diaphragmatic	and	liver	surfaces.	
Pleural	involvement	is	also	seen.	Other	extraperitoneal	or	extrapleural	
sites	 are	 relatively	 uncommon,	 but	 can	 occur.1,10–12	 After	 system-
atic	pathologic	analysis	has	excluded	a	tubal	or	ovarian	site	of	origin,	
malignancies	that	appear	to	arise	primarily	on	the	peritoneum	have	an	
identical	spread	pattern,	and	frequently	may	involve	the	ovaries	and	
fallopian	tubes	secondarily.	These	“peritoneal”	tumors	are	thought	to	
arise	in	endosalpingiosis.
1.2 | Classification rules
Although	CT	scans	can	delineate	 the	 intra-	abdominal	spread	of	dis-
ease	to	a	certain	extent,	ovarian,	fallopian	tube,	and	peritoneal	can-
cers	 should	 be	 staged	 surgically.	 Operative	 findings	 determine	 the	
precise	histologic	diagnosis,	stage,	and	therefore	the	prognosis,	of	the	
patient.1,9,10,12–14
In	selected	patients	with	advanced-	stage	disease,	it	may	be	appro-
priate	 to	 initiate	 chemotherapy	 prior	 to	 surgical	 intervention,	 and	 in	
these	cases,	there	should	be	histologic	or	cytologic	confirmation	of	the	
diagnosis	prior	to	starting	neoadjuvant	chemotherapy	(see	5.2.2.	below).
Chest	radiograms	may	serve	as	a	screen	for	pleural	effusions.	As	
distant	metastases	are	 infrequent,	 there	 is	no	requirement	for	other	
radiological	evaluation	unless	symptomatic.	Serum	CA125	levels	may	
be	useful	in	determining	response	to	chemotherapy,	but	they	do	not	
contribute	to	staging.
1.2.1 | Fallopian tube involvement
Fallopian	tube	involvement	can	be	divided	into	three	categories.	In	the	
first,	an	obvious	intraluminal	and	grossly	apparent	fallopian	tube	mass	
is	 seen	with	 tubal	 intraepithelial	 carcinoma	 (carcinoma	 in	 situ)	 that	
is	presumed	to	have	arisen	in	the	fallopian	tube.	These	cases	should	
be	staged	surgically	with	a	histologic	confirmation	of	disease.	Tumor	
extension	 into	the	submucosa	or	muscularis	and	to	and	beyond	the	
serosa	 can	 therefore	 be	 defined.	 These	 features,	 together	with	 the	
laterality	and	the	presence	or	absence	of	ascites,	should	all	be	taken	
into	consideration.1,3,6,7
In	 the	 second	 scenario,	 a	widespread	 serous	 carcinoma	 is	 asso-
ciated	 with	 a	 tubal	 intraepithelial	 carcinoma.	 A	 visible	 mass	 in	 the	
endosalpinx	may	 not	 be	 seen	 but	 the	 histologic	 findings	 should	 be	
noted	in	the	pathology	report	since	they	may	indicate	a	fallopian	tube	
primary.	Tumors	obliterating	both	fallopian	tube	and	ovary	may	belong	
to	this	group	but	whether	a	presumptive	assignment	of	a	tubal	origin	
can	be	made	in	such	cases	is	controversial	given	that	tubal	intraepithe-
lial	carcinoma	cannot	be	confirmed.
In	 the	 third	 scenario—	 risk-	reducing	 salpingo-	oophorectomy—
tubal	 intraepithelial	carcinoma	may	be	the	only	finding.	 It	 should	be	
reported	as	originating	in	the	fallopian	tube	and	managed	accordingly.	
The	majority	of	early	serous	cancers	detected	are	found	in	the	fallo-
pian	tube,	irrespective	of	genetic	risk.15,16
1.2.2 | FIGO staging
The	 updated,	 revised	 FIGO	 staging	 system	 combines	 the	 classifica-
tion	for	ovarian,	fallopian	tube,	and	peritoneum	cancer.	It	is	based	on	
findings	made	mainly	through	surgical	exploration	(as	outlined	above).	
Table	1	presents	 the	2014	FIGO	staging	classification	 for	cancer	of	
the	ovary,	fallopian	tube,	and	peritoneum.	The	equivalents	within	the	
Union	for	International	Cancer	Control	(UICC)	TNM	classification	are	
presented	in	Table	2.
In	 addition	 to	 these	 changes,	 several	 other	modifications	 of	 the	
former	staging	system	have	been	made	to	better	prospectively	capture	
the	data.	Stage	IC	 is	now	divided	 into	 three	categories:	 IC1	 (surgical	
spill);	IC2	(capsule	ruptured	before	surgery	or	tumor	on	ovarian	or	fallo-
pian	tube	surface);	and	IC3	(malignant	cells	in	the	ascites	or	peritoneal	
washings).	Stage	IIC	has	been	eliminated.	The	updated	staging	includes	
a	 revision	 of	 the	 Stage	IIIC	 based	 on	 spread	 to	 the	 retroperitoneal	
lymph	nodes	alone	without	intraperitoneal	dissemination,	because	an	
analysis	of	 these	patients	 indicates	 that	 their	 survival	 is	 significantly	
better	than	those	who	have	intraperitoneal	dissemination.17	This	cat-
egory	 is	now	subdivided	 into	 IIIA1(i)	 (metastasis	≤10	mm	 in	greatest	
dimension),	 and	 IIIA1(ii)	 (metastasis	 >10	mm	 in	 greatest	 dimension).	
Stage	IIIA2	 is	 now	 “microscopic	 extrapelvic	 peritoneal	 involvement	
with	or	without	positive	retroperitoneal	lymph	node”	metastasis.	The	
wording	of	Stage	IIIB	has	been	modified	to	reflect	the	lymph	node	sta-
tus.	Stage	IVB	now	includes	metastases	to	the	inguinal	lymph	nodes.
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1.2.2.1 | Regional lymph nodes (N)
1.	 NX:	 Regional	 lymph	 nodes	 cannot	 be	 assessed.
2.	 N0:	No	regional	lymph	node	metastasis.
3.	 N1:	Regional	lymph	node	metastasis.
1.2.2.2 | Distant metastasis (M)
1.	 MX:	 Distant	 metastasis	 cannot	 be	 assessed.
2.	 M0:	No	distant	metastasis.
3.	 M1:	Distant	metastasis	(excluding	peritoneal	metastasis).
T A B L E  1  FIGO	staging	classification	for	cancer	of	the	ovary,	fallopian	tube,	and	peritoneum.
Stage I: Tumor confined to ovaries or fallopian tube(s)
T1-	N0-	M0
IA:	Tumor	limited	to	1	ovary	(capsule	intact)	or	fallopian	tube;	no	tumor	on	ovarian	or	fallopian	tube	surface;	no	malignant	 
cells	in	the	ascites	or	peritoneal	washings
T1a-	N0-	M0
IB:	Tumor	limited	to	both	ovaries	(capsules	intact)	or	fallopian	tubes;	no	tumor	on	ovarian	or	fallopian	tube	surface;	no	 
malignant	cells	in	the	ascites	or	peritoneal	washings
T1b-	N0-	M0
IC:	Tumor	limited	to	1	or	both	ovaries	or	fallopian	tubes,	with	any	of	the	following:
IC1:	Surgical	spill
T1c1-	N0-	M0
IC2:	Capsule	ruptured	before	surgery	or	tumor	on	ovarian	or	fallopian	tube	surface
T1c2-	N0-	M0
IC3:	Malignant	cells	in	the	ascites	or	peritoneal	washings
T1c3-	N0-	M0
Stage II: Tumor involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer
T2-	N0-	M0
IIA:	Extension	and/or	implants	on	uterus	and/or	fallopian	tubes	and/or	ovaries
T2a-	N0-	M0
IIB:	Extension	to	other	pelvic	intraperitoneal	tissues
T2b-	N0-	M0
Stage III: Tumor involves 1 or both ovaries or fallopian tubes, or peritoneal cancer, with cytologically or histologically  
confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
T1/T2-	N1-	M0
IIIA1:	Positive	retroperitoneal	lymph	nodes	only	(cytologically	or	histologically	proven):
IIIA1(i)	Metastasis	up	to	10	mm	in	greatest	dimension
IIIA1(ii)	Metastasis	more	than	10	mm	in	greatest	dimension
IIIA2:	Microscopic	extrapelvic	(above	the	pelvic	brim)	peritoneal	involvement	with	or	without	positive	retroperitoneal	 
lymph	nodes
T3a2-	N0/N1-	M0
IIIB:	Macroscopic	peritoneal	metastasis	beyond	the	pelvis	up	to	2	cm	in	greatest	dimension,	with	or	without	metastasis	to	 
the	retroperitoneal	lymph	nodes
T3b-	N0/N1-	M0
IIIC:	Macroscopic	peritoneal	metastasis	beyond	the	pelvis	more	than	2	cm	in	greatest	dimension,	with	or	without	metastasis	 
to	the	retroperitoneal	lymph	nodes	(includes	extension	of	tumor	to	capsule	of	liver	and	spleen	without	parenchymal	 
involvement	of	either	organ)
T3c-	N0/N1-	M0
Stage IV: Distant metastasis excluding peritoneal metastases
Stage	IVA:	Pleural	effusion	with	positive	cytology
Stage	IVB:	Parenchymal	metastases	and	metastases	to	extra-	abdominal	organs	(including	inguinal	lymph	nodes	and	 
lymph	nodes	outside	of	the	abdominal	cavity)
Any	T,	any	N,	M1
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1.3 | Histopathologic classification
The	majority	of	cases	of	ovarian	cancer	are	of	epithelial	origin.	FIGO	
endorses	the	WHO	histologic	typing	of	epithelial	ovarian	tumors.	It	is	
recommended	that	all	ovarian	epithelial	tumors	be	subdivided	accord-
ing	to	the	classification	given	below.18
The	histologic	classification	of	ovarian,	fallopian	tube,	and	perito-
neal	neoplasia	is	as	follows:
1.	 Serous	 tumors.
2.	 Mucinous	tumors.
3.	 Endometrioid	tumors.
4.	 Clear	cell	tumors.
5.	 Brenner	tumors.
6.	 Undifferentiated	carcinomas	(this	group	of	malignant	tumors	is	of	
epithelial	 structure,	 but	 they	 are	 too	 poorly	 differentiated	 to	 be	
placed	in	any	other	group).
7.	 Mixed	 epithelial	 tumors	 (these	 tumors	 are	 composed	 of	 two	 or	
more	of	the	five	major	cell	types	of	common	epithelial	tumors.	The	
types	are	usually	specified).
8.	 Cases	with	high-grade	serous	carcinoma	in	which	the	ovaries	and	
fallopian	tubes	appear	to	be	incidentally	involved	and	not	the	pri-
mary	origin	can	be	labeled	as	peritoneal	carcinoma	or	serous	carci-
noma	of	undesignated	site,	at	the	discretion	of	the	pathologist.
Epithelial	tumors	of	the	ovary	and	fallopian	tube	are	further	sub-
classified	by	histologic	grading,	which	can	be	correlated	with	progno-
sis.	This	grading	system	does	not	apply	to	nonepithelial	tumors.19 Two 
grading	systems	are	applied.	For	non-	serous	carcinomas	(most	endo-
metrioid	and	mucinous),	grading	is	identical	to	that	used	in	the	uterus,	
based	on	architecture	with	a	one-	step	upgrade	if	there	is	prominent	
nuclear	atypia,	as	follows:
1.	 GX:	 Grade	 cannot	 be	 assessed.
2.	 G1:	Well	differentiated.
3.	 G2:	Moderately	differentiated.
4.	 G3:	Poorly	differentiated.
Serous	carcinomas	are	 the	most	common	 in	both	 the	ovary	and	
tube.	More	than	90%	of	fallopian	tube	carcinomas	are	serous	or	high-	
grade	 endometrioid	 adenocarcinoma.	 Other	 cell	 types	 have	 been	
reported,	 but	 are	 rare.1,2,20	 Serous	 carcinomas	 are	 graded	 in	 a	 two-	
grade	 system	befitting	 their	 biology.	High-	grade	 serous	 carcinomas,	
including	both	 classic	 appearing	 and	 those	with	 SET	 features	 (solid,	
endometrioid-	like,	 and	 transitional)	 carry	 a	 high	 frequency	of	muta-
tions	in	TP53.21–23	Low-	grade	serous	carcinomas	are	often	associated	
with	borderline	or	atypical	proliferative	serous	tumors,	often	contain	
mutations	in	BRAF	and	KRAS	and	contain	wild-	type	TP53.	Most	“mod-
erately	differentiated”	serous	carcinomas	carry	mutations	in	TP53	and	
should	be	combined	with	the	high-	grade	tumors.19,22–24
Nonepithelial	cancers,	although	uncommon,	are	extremely	import-
ant.	These	include	granulosa	cell	tumors,	germ	cell	tumors,	sarcomas,	and	
lymphomas.	They	are	discussed	below	as	separate	entities.	Metastatic	
neoplasms	 to	 the	 ovary,	 such	 as	 tumors	 arising	 in	 the	 breast,	 lower	
reproductive	tract	sites	(cervix	or	uterine	carcinomas)	and	gastrointes-
tinal	tract	 (signet	ring	cell	 [Krukenberg]	carcinomas,	 low	grade	appen-
diceal	or	pancreaticobiliary	mucinous	tumors	and	other	neoplasms)	are	
graded	and	staged	in	accordance	with	their	respective	sites	of	origin.1,2
2  | EPIDEMIOLOGY
Malignant	tumors	of	the	ovaries	occur	at	all	ages	with	variation	in	his-
tologic	subtype	by	age.	For	example,	in	women	younger	than	20	years	
T A B L E  2  Cancer	of	the	ovary,	fallopian	tube	and	peritoneum:	
FIGO	staging	(2014)	compared	with	TNM	classification.a
FIGO (designate primary: 
Tov, Tft, Tp, or Tx)
UICC
T N M
Stage
IA T1a N0 M0
IB T1b N0 M0
IC T1c N0 M0
IIA T2a N0 M0
IIB T2b N0 M0
IIIA T3a N0 M0
T3a N1 M0
IIIB T3b N0 M0
T3b N1 M0
IIIC T3c N0–1 M0
T3c N1 M0
IV Any	T Any	N M1
Regional	nodes	(N)
Nx Regional	lymph	nodes	cannot	be	
assessed
N0 No	regional	lymph	node	metastasis
N1 Regional	lymph	node	metastasis
Distant	metastasis	(M)
Mx Distant	metastasis	cannot	be	assessed
M0 No	distant	metastasis
M1 Distant	metastasis	(excluding	peritoneal	
metastasis)
Notes: 1.	 The	 primary	 site—that	 is,	 ovary,	 fallopian	 tube,	 or	 peritoneum—
should	be	designated	where	possible.	In	some	cases,	it	may	not	be	possible	to	
clearly	delineate	the	primary	site,	and	these	should	be	listed	as	“undesignated.”	
2.	The	histologic	type	should	be	recorded.	3.	The	staging	includes	a	revision	of	
the	Stage	III	patients	and	allotment	to	Stage	IIIA1	is	based	on	spread	to	the	
retroperitoneal	 lymph	nodes	without	 intraperitoneal	dissemination,	because	
an	analysis	of	these	patients	indicates	that	their	survival	is	significantly	better	
than	those	who	have	intraperitoneal	dissemination.	4.	Involvement	of	retrop-
eritoneal	 lymph	 nodes	 must	 be	 proven	 cytologically	 or	 histologically.	 5.	
Extension	of	tumor	from	omentum	to	spleen	or	liver	(Stage	IIIC)	should	be	dif-
ferentiated	from	isolated	parenchymal	splenic	or	liver	metastases	(Stage	IVB).
aSource:	Prat	J;	FIGO	Committee	on	Gynecologic	Oncology.	Staging	classi-
fication	 for	 cancer	 of	 the	 ovary,	 fallopian	 tube,	 and	 peritoneum.	 Int	 J	
Gynecol	Obstet.	2014;124:1–5.
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of	age,	germ	cell	tumors	predominate,	while	borderline	tumors	typi-
cally	occur	in	women	in	their	30s	and	40s—10	or	more	years	younger	
than	in	women	with	invasive	epithelial	ovarian	cancers,	which	mostly	
occur	after	the	age	of	50	years.
The	lifetime	risk	of	a	woman	in	the	USA	developing	ovarian	cancer	
is	approximately	1	in	70.	Approximately	23%	of	gynecologic	cancers	
are	ovarian	in	origin,	but	47%	of	all	deaths	from	cancer	of	the	female	
genital	 tract	occur	 in	women	with	ovarian	cancer.	Overall,	epithelial	
ovarian	cancer	accounts	for	4%	of	all	new	cancer	diagnoses	in	women	
and	5%	of	all	cancer-	related	deaths.1,2,25
The	overall	incidence	of	epithelial	tumors	varies	from	9	to	17	per	
100	000	and	is	highest	in	high-	income	countries,	with	the	exception	of	
Japan.26	However,	this	 incidence	rate	increases	proportionately	with	
age.	The	 largest	number	of	patients	with	epithelial	ovarian	cancer	 is	
found	in	the	60–64	years	age	group.	The	median	age	is	about	a	decade	
earlier	in	low-	income	countries.
Established	risk	factors	for	epithelial	ovarian	tumors	include	repro-
ductive	risk	factors.	Women	who	have	never	had	children	are	twice	
as	likely	to	develop	this	disease.	First	pregnancy	at	an	early	age,	early	
menopause,	and	the	use	of	oral	contraceptives	have	been	associated	
with	lower	risks	of	ovarian	cancer.27	The	relationship	of	these	variables	
to	fallopian	tube	cancer	is	unclear.
As	 noted	 above,	 it	 has	 been	 previously	 presumed	 that	 fallopian	
tube	malignancies	were	 rare;	 however,	 this	 has	 been	 challenged	 by	
evidence	to	show	that	many	tumors	that	were	classified	as	serous	car-
cinomas	of	the	ovary	or	peritoneal	cancers	appear	to	have	their	origin	
in	the	fallopian	tube.3–7	When	the	origin	is	uncertain,	the	convention	
of	designating	all	serous	cancers,	as	originating	in	the	ovary	should	no	
longer	be	used	and	the	term	“undesignated	origin”	may	be	applied	at	
the	discretion	of	the	pathologist.18
2.1 | Genetics
Hereditary	factors	are	implicated	in	approximately	20%	of	ovarian,	fal-
lopian	tube,	and	peritoneal	cancers28–32:
1.	 Most	hereditary	ovarian	cancers	are	due	to	pathogenic	mutations	
in	 either	 the	 BRCA1 or BRCA2	 genes.	 At	 least	 15%	 of	 women	
with	 high-grade	 nonmucinous	 ovarian	 cancers	 have	 germline	
mutations	 in	 BRCA1/2	 and,	 importantly,	 almost	 40%	 of	 these	
women	 do	 not	 have	 a	 family	 history	 of	 breast/ovarian	 cancer.	
All	women	with	high-grade	nonmucinous	invasive	ovarian	cancers	
should	 be	 offered	 genetic	 testing	 even	 if	 they	 do	 not	 have	 a	
family	 history	 of	 breast/ovarian	 cancer.
2.	 Inherited	 deleterious	 mutations	 in	 BRCA1	 and	 BRCA2	 are	 the	
major	genetic	risk	factors.	Women	who	carry	germline	mutations	
in BRCA1	and	BRCA2	have	a	substantially	increased	risk	of	ovarian,	
tubal,	 and	 peritoneal	 cancer—about	 20%–50%	with	 BRCA1	 and	
10%–20%	with	BRCA2.29–32	Typically,	 these	cancers	occur	at	an	
earlier	age	than	sporadic	cancers,	particularly	in	BRCA1	mutation	
carriers,	with	a	median	age	of	diagnosis	in	the	mid-40s.
3.	 There	are	a	number	of	other	low-	to	moderate-penetrance	genes	
that	 can	 also	 predispose	 to	 ovarian,	 fallopian	 tube,	 or	 peritoneal	
cancer.	A	recent	study	of	next	generation	sequencing	of	constitu-
tional	DNA	samples	 from	1915	women	with	ovarian	cancer	was	
carried	out	to	identify	germline	mutations	using	a	panel	of	20	genes	
including	BRCA1	and	BRCA2,	DNA	mismatch	repair	genes,	double	
stranded	DNA	break	repair	genes	such	as	CHEK2	and	ATM,	as	well	
as	the	BRCA1-associated	complex	or	the	BRCA2/Fanconi	Anemia	
pathway	genes	(including	BRIP1, BARD1, PALB2, RAD50, RAD51C,	
and	 RAD51D,	 among	 others).	 About	 80%	 of	 mutations	 were	 in	
BRCA1 or BRCA2.	About	3%	of	patients	carried	mutations	 in	 the	
Fanconi	Anemia	pathway	genes,	while	only	0.4%	had	mutations	in	
mismatch	 repair	genes.33	 In	an	earlier	 similar	 study	 that	 included	
360	 patients,	 24%	 carried	 germline	 loss-of-function	 mutations	
including	18%	in	BRCA1 or BRCA2	and	6%	in	BARD1,	BRIP1,	CHEK2,	
MRE11A,	MSH6,	NBN,	PALB2,	RAD50,	RAD51C,	or	TP53.34,35
4.	 Inherited	mutations	in	the	mismatch	repair	genes	associated	with	
Lynch	syndrome	type	II.	Women	carrying	these	mutations	have	an	
increased	risk	of	a	number	of	cancers	including	colon,	endometrial,	
and	ovarian	cancer.	Typically,	 the	ovarian	cancers	 that	occur	 are	
endometrioid	or	clear	cell	histologically	and	are	usually	Stage	I.35
Women	with	a	strong	family	history	of	epithelial	ovarian,	 fallopian	
tube,	or	peritoneal	cancers,	particularly	if	there	is	a	documented	germline	
BRCA	mutation,	are	advised	to	have	a	risk-	reducing	bilateral	salpingo-	
oophorectomy	 after	 appropriate	 counseling	 and	 at	 the	 completion	 of	
childbearing.	All	women	who	are	suspected	of	carrying	a	BRCA	germ-
line	mutation,	based	on	family	history	or	young	age	of	diagnosis	and	a	
high-	grade	serous	or	high-	grade	endometrioid	cancer,	should	be	offered	
genetic	 testing.	BRCA	mutations	may	also	occur	 in	women	without	 a	
family	history	of	breast/ovarian	 cancer,	 and	genetic	 testing	 should	be	
considered	 in	 patients	 from	ethnic	 groups	where	 there	 is	 a	 high	 inci-
dence	 of	 founder	 mutations	 (e.g.	 Ashkenazi	 Jewish	 ancestry),	 and	 in	
women	with	high-	grade	serous	cancers	under	the	age	of	70	years.26–30 
Australian	 guidelines	 advise	 that	 all	 women	 with	 invasive	 epithelial	
ovarian	cancer	apart	 from	mucinous	cancers	diagnosed	under	the	age	
of	70	should	be	offered	BRCA	mutation	testing	independent	of	family	
history	and	histologic	subtype.36	In	contrast,	the	Society	of	Gynecologic	
Oncology	(SGO)	and	National	Comprehensive	Cancer	Network	(NCCN)	
guidelines	recommend	that	all	women	diagnosed	with	ovarian,	fallopian	
tube,	or	peritoneal	carcinoma,	regardless	of	age	or	family	history,	should	
receive	 genetic	 counseling	 and	 be	 offered	 genetic	 testing.37	Women	
whose	family	history	suggests	Lynch	syndrome	type	II	should	undergo	
appropriate	genetic	counseling	and	testing.
3  | SCREENING
To	date,	there	are	no	documented	effective	screening	methods	that	
reduce	the	mortality	of	ovarian,	fallopian	tube,	or	peritoneal	cancers.	
Studies	using	CA125,	ultrasonography	of	the	pelvis,	and	pelvic	exami-
nation	do	not	have	an	acceptable	 level	of	sensitivity	and	specificity,	
based	on	 trials	 carried	out	 in	women	 in	 the	 general	 population	 and	
those	 in	 the	 high-	risk	 population.	 The	US	 Preventive	 Services	 Task	
Force	 recommends	 against	 screening	 asymptomatic	 women	 for	
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ovarian	 cancer	with	 pelvic	 examination,	 pelvic	 ultrasound,	 or	 serum	
tumor	 marker	 measurements.38	 The	 low	 prevalence	 of	 disease	 and	
lack	of	high-	quality	screening	methods	make	it	more	likely	to	obtain	
false-	positive	 results	 leading	 to	unnecessary	 interventions.	A	 recent	
study	of	multimodal	screening	using	CA125	based	on	a	risk	of	ovarian	
cancer	algorithm	(ROCA)	every	4	months	and	transvaginal	ultrasound	
annually	 or	 earlier	where	 indicated	by	 the	ROCA	 in	women	 at	 high	
risk	 of	 ovarian	 cancer	 reported	 that	 screening	 was	 associated	 with	
a	 low	 rate	of	high-	volume	disease	at	primary	 surgery	and	very	high	
rates	of	no	 residual	 disease	 after	 surgery.38	Given	 that	 the	majority	
of	women	with	advanced	stage	ovarian	cancer,	even	with	complete	
resection,	will	relapse	after	chemotherapy,	this	does	not	seem	to	be	a	
good	alternative	to	risk-	reducing	surgery.	The	authors	of	the	screen-
ing	study	concluded	that	risk-	reducing	salpingectomy-	oophorectomy	
remains	the	treatment	choice	for	women	at	high	risk	of	ovarian/fal-
lopian	tube	cancer.38
Women	 at	 increased	 genetic	 risk	 should	 be	 encouraged	 to	 con-
sider	risk-	reducing	bilateral	salpingo-	oophorectomy,	as	this	is	the	most	
effective	way	to	reduce	mortality	in	this	population	of	women.39,40	An	
ACOG	bulletin	has	recommended	that	opportunistic	(at	the	time	of	a	
clinically	indicated	hysterectomy)	bilateral	salpingectomy	be	considered	
in	women	not	at	genetic	risk	who	wish	to	retain	their	ovaries	as	a	way	
to	reduce	their	risk	of	later	developing	high-	grade	serous	carcinomas.41
4  | DIAGNOSIS
Patients	with	epithelial	ovarian	cancers	confined	to	the	ovary	or	fal-
lopian	tube	at	 initial	diagnosis	have	a	very	good	prognosis.42–45 The 
symptoms	are	often	very	insidious	and	the	duration	of	symptoms	not	
very	different	between	patients	with	early	 stage	or	advanced	stage	
disease.13,14	This	may	reflect	the	different	biological	behavior	of	the	
various	 histologic	 subtypes;	 for	 example,	 grade	1	 serous,	 clear	 cell,	
mucinous,	 and	 endometrioid	 cancers	 are	 commonly	 early	 stage	 at	
presentation,	whereas	high-	grade	serous	cancers	are	most	often	Stage	
III	because	of	early	dissemination	by	a	more	aggressive	cancer.	Tumor	
markers	 such	 as	 human	 gonadotropin	 (hCG)	 and	 alpha-	fetoprotein	
(AFP)	are	mandatory	to	exclude	germ	cell	tumors	in	younger	patients	
with	a	pelvic	mass	or	suspicious	enlargement	of	an	ovary.
Approximately	 two-	thirds	of	 all	 epithelial	 “ovarian”	 cancers	 are	
Stage	III	or	Stage	IV	at	diagnosis.	Presenting	symptoms	include	vague	
abdominal	 pain	 or	 discomfort,	 menstrual	 irregularities,	 dyspepsia,	
and	other	mild	digestive	disturbances,	which	may	have	been	pres-
ent	for	only	a	few	weeks.13,14,46	As	the	disease	progresses,	abdom-
inal	 distention	 and	 discomfort	 from	 ascites	 generally	worsen,	 and	
may	be	associated	with	respiratory	symptoms	from	increased	intra-	
abdominal	pressure	or	from	the	transudation	of	fluid	into	the	pleural	
cavities.	Abnormal	vaginal	bleeding	is	an	uncommon	symptom.
Serous	fallopian	tube	and	peritoneal	cancers	present	the	same	as	
ovarian	cancer.	Past	analyses	have	been	biased	because	many	fallo-
pian	tube	cancers	have	been	presumed	to	arise	in	the	ovaries.
A	detailed	medical	history	must	be	taken	to	ascertain	possible	risk	
factors,	history	of	other	cancers,	and	history	of	cancer	 in	the	family.	
Then	a	complete	physical	examination,	including	general,	breast,	pel-
vic,	and	rectal	examination,	must	be	performed.1
Prior	to	surgery	a	chest	radiograph	should	be	taken	to	screen	for	
a	pleural	 effusion	and	a	CT	 scan	of	 the	abdomen	and	pelvis	 should	
be	 performed	 to	 delineate	 the	 extent	 of	 intra-	abdominal	 disease.	
However,	in	the	absence	of	extra-	abdominopelvic	disease,	radiologi-
cal	scanning	does	not	replace	surgical	staging	with	laparotomy.	Tumor	
markers	including	CA125,	and	carcinoembryonic	antigen	(CEA)	should	
be	considered.1	With	a	high	CA125	level,	the	most	common	diagnosis	
would	be	epithelial	ovarian,	fallopian	tube,	or	peritoneal	cancer.
A	gastric	or	colonic	primary	with	metastases	 to	 the	ovaries	may	
mimic	ovarian	cancer,	and	if	the	CEA	is	elevated,	this	should	be	con-
sidered.	A	ratio	of	more	than	25:1	(CA-	125	and	CEA)	favors	an	ovarian	
primary	though	it	does	not	completely	rule	out	a	primary	in	the	gas-
trointestinal	tract.47
A	current	mammogram	should	be	considered	as	patients	are	fre-
quently	in	the	age	group	where	breast	cancer	is	prevalent.	A	colonos-
copy	is	indicated	when	symptoms	suggest	possible	bowel	cancer.1
The	following	factors	point	to	the	presence	of	a	malignancy,	and	
are	useful	in	the	clinical	assessment	of	masses:
1.	 Age	 of	 the	 patient	 (young	 for	 germ	 cell,	 older	 for	 epithelial	
malignancies).
2.	 Bilaterality.
3.	 Tumor	fixation	clinically.
4.	 Ascites.
5.	 Ultrasonographically	complex,	especially	if	solid	areas.
6.	 CT	finding	of	metastatic	nodules.
7.	 Elevated	tumor	markers.
5  | PRIMARY SURGERY
In	general,	the	prognosis	of	epithelial	ovarian,	fallopian,	and	peritoneal	
malignancies	is	independently	affected	by	the	following1,48,49:
1.	 Stage	 of	 the	 cancer	 at	 diagnosis.
2.	 Histologic	type	and	grade.
3.	 Maximum	diameter	of	residual	disease	after	cytoreductive	surgery.
5.1 | Staging laparotomy
A	thorough	staging	laparotomy	is	an	important	part	of	early	manage-
ment.	If	the	preoperative	suspicion	is	malignancy,	a	laparotomy	should	
be	performed.	If	there	is	no	visible	or	palpable	evidence	of	metastasis,	
the	following	should	be	performed	for	adequate	staging1,10,11,13,14:
1.	 Careful	 evaluation	 of	 all	 peritoneal	 surfaces.
2.	 Retrieval	of	any	peritoneal	fluid	or	ascites.	If	there	is	none,	wash-
ings	of	the	peritoneal	cavity	should	be	performed.
3.	 Infracolic	omentectomy.
4.	 Selective	 lymphadenectomy	 of	 the	 pelvic	 and	 para-aortic	 lymph	
nodes,	at	least	ipsilateral	if	the	malignancy	is	unilateral.
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5.	 Biopsy	or	resection	of	any	suspicious	lesions,	masses,	or	adhesions.
6.	 Random	peritoneal	biopsies	of	normal	surfaces,	including	from	the	
undersurface	of	 the	 right	hemidiaphragm,	bladder	 reflection,	cul-
de-sac,	right	and	left	paracolic	recesses,	and	both	pelvic	sidewalls.
7.	 Total	 abdominal	 hysterectomy	 and	 bilateral	 salpingo-oophorec-
tomy	in	most	cases.
8.	 Appendectomy	for	mucinous	tumors.
Upon	opening	the	abdominopelvic	cavity,	the	peritoneal	fluid	should	
be	sent	for	cytology.	In	the	absence	of	ascites,	irrigation	should	be	per-
formed	and	washings	sent	for	cytology.
The	laparotomy	should	proceed	with	a	detailed	examination	of	the	
contents,	 including	 all	 of	 the	 peritoneal	 surfaces.	 In	 addition	 to	 the	
suspicious	sites,	biopsies	from	the	peritoneal	reflection	of	the	bladder,	
the	posterior	cul-	de-	sac,	both	paracolic	gutters,	subdiaphragmatic	sur-
faces,	and	both	pelvic	sidewalls	should	be	taken.	The	primary	tumor,	if	
limited	to	the	ovary,	should	be	examined	to	look	for	capsular	rupture.	
All	obvious	sites	of	tumor	must	be	removed	wherever	possible	in	addi-
tion	to	total	hysterectomy	and	bilateral	salpingo-	oophorectomy.	The	
omentum,	pelvic,	and	para-	aortic	lymph	nodes	should	be	removed	for	
histologic	examination.
In	younger	women,	fertility	may	be	an	issue.	In	these	patients,	con-
servative	 surgery,	with	 preservation	 of	 the	 uterus	 and	 contralateral	
ovary,	should	be	considered	after	informed	consent.43
Clinical	 judgment	 is	 important	 in	 the	 approach	 to	 a	 pelvic	
mass	 in	 the	 young,	 reproductive-	aged	 woman.	 If	 the	 suspicion	
is	 strong	 for	 malignancy,	 open	 laparotomy	 is	 generally	 indicated.	
Laparoscopy	may	be	more	appropriate	if	the	suspicion	is	more	for	
benign	disease,	where	tumor	markers	(including	hCG	and	AFP)	are	
normal.	A	 biopsy	 of	 any	 suspicious	 lesion	 can	 be	 performed	 and	
frozen	 section	 obtained	 in	 order	 to	 proceed	 expeditiously	 with	
definitive	surgery.
Ovaries	and	fallopian	tubes	should	be	evaluated	as	thoroughly	as	
possible	to	establish	the	site	of	origin.	If	visible,	the	entire	tube,	partic-
ularly	the	distal	portion,	should	be	submitted	for	pathology	and	exam-
ined	using	the	SEE-	FIM	protocol.32	Ovaries	should	be	scrutinized	for	
coexisting	endometriotic	cysts,	adenofibromas,	or	other	benign	condi-
tions	that	could	serve	as	a	nidus	of	tumor	development.
5.2 | Cytoreductive (debulking) surgery for advanced 
stage disease
5.2.1 | Primary debulking
At	least	two-	thirds	of	patients	with	ovarian	cancer	present	with	Stage	III	
or	IV	disease.	This	may	affect	the	performance	status	and	fitness	for	sur-
gery.	However,	the	most	important	prognostic	indicator	in	patients	with	
advanced	stage	ovarian	cancer	 is	 the	volume	of	 residual	disease	after	
surgical	 debulking.	 Therefore,	 patients	 whose	 medical	 condition	 per-
mits	should	generally	undergo	a	primary	laparotomy	with	total	abdomi-
nal	hysterectomy,	bilateral	salpingo-	oophorectomy,	omentectomy,	and	
maximal	attempt	at	optimal	cytoreduction.1,48–50	This	may	necessitate	
bowel	resection,	and	occasionally,	partial	or	complete	resection	of	other	
organs.	 Systematic	 pelvic	 and	 para-	aortic	 lymphadenectomy	 of	 non-	
enlarged	nodes	does	not	improve	overall	survival,	when	compared	with	
removal	of	bulky	nodes	only,	although	there	is	a	modest	improvement	in	
progression-	free	survival.51 Level of Evidence A
5.2.2 | Interval debulking
In	selected	patients	with	cytologically	proven	Stage	IIIC	and	IV	disease	
who	may	not	be	good	surgical	candidates,	3–4	cycles	of	neoadjuvant	
chemotherapy	 (NACT)	 may	 be	 given	 initially,	 followed	 by	 interval	
debulking	 surgery	 (IDS)	 and	 additional	 chemotherapy	 as	 demon-
strated	in	the	EROTC	and	CHORUS	Trials.52,53	These	two	randomized	
prospective	trials	showed	that	in	selected	patients,	interval	debulking	
surgery	after	neoadjuvant	chemotherapy	showed	equivalent	survival	
with	 less	 morbidity	 compared	 with	 primary	 cytoreductive	 surgery.	
NACT	followed	by	IDS	may	be	particularly	useful	 in	patients	with	a	
poor	performance	status,	significant	medical	co-	morbidities,	visceral	
metastases,	and	those	who	have	large	pleural	effusions	and/or	gross	
ascites.54	In	selected	patients	whose	primary	cytoreduction	is	consid-
ered	suboptimal,	particularly	if	a	gynecologic	oncologist	did	not	per-
form	the	initial	operation,	interval	debulking	may	be	considered	after	
2–3	cycles	of	systemic	chemotherapy.1,52,53,55	Pathologic	assessment	
for	residual	tumor	following	neoadjuvant	therapy	will	enable	an	esti-
mate	of	residual	disease	and	pathological	response.56	There	are	recent	
data	to	indicate	that	patients	who	have	a	good	pathological	response	
have	a	better	outcome.	A	histopathologic	scoring	system	for	measur-
ing	response	to	neoadjuvant	chemotherapy	has	been	developed	and	
validated	by	Bohm	et	al.57	who	reported	criteria	for	defining	a	chemo-
therapy	 response	 score	 (CRS)	 based	 on	 a	 three-	tier	 system.	A	CRS	
3	(complete	or	near	complete	pathological	response)	was	associated	
with	a	better	prognosis.	Recently,	these	results	have	been	validated	in	
an	independent	West	Australian	cohort.58
6  | CHEMOTHERAPY
6.1 | Chemotherapy for early stage cancer
The	prognosis	of	patients	with	adequately	staged	tumors	with	Stage	
IA	and	Stage	IB	grade	1–2	epithelial	cancers	of	the	ovary	is	very	good;	
adjuvant	 chemotherapy	 does	 not	 provide	 additional	 benefits	 and	 is	
not	 indicated.	 For	 higher-	grade	 tumors	 and	 for	 patients	with	 Stage	
IC	disease,	adjuvant	platinum-	based	chemotherapy	 is	given	to	most	
patients,	although	there	has	been	debate	about	the	absolute	survival	
benefit	in	women	with	Stage	IA	and	IB	cancers	who	have	had	thorough	
surgical	 staging.42	 All	 patients	 with	 Stage	II	 disease	 should	 receive	
adjuvant	 chemotherapy.	 The	 optimal	 number	 of	 cycles	 in	 patients	
with	Stage	I	disease	has	not	been	definitively	established,	but	typically	
between	3	and	6	cycles	are	administered.	The	Gynecologic	Oncology	
Group	 (GOG)	157	study	suggested	 that	3	cycles	of	carboplatin	and	
paclitaxel	was	equivalent	to	6	cycles,	but	in	subgroup	analysis,	6	cycles	
appeared	superior	in	patients	with	high-	grade	serous	cancers.50
There	is	no	evidence	to	support	adjuvant	therapy	for	carcinoma	in	situ	
of	the	fallopian	tube	and	it	is	not	recommended.1,2,44 Level of Evidence A
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6.2 | Chemotherapy for advanced stage 
ovarian cancer
Patients	who	have	had	primary	cytoreduction	should	receive	chemo-
therapy	 following	 surgery1,59	 (Table	3).	 The	 accepted	 standard	 is	 6	
cycles	of	platinum-	based	combination	chemotherapy,	with	a	platinum	
(carboplatin	or	 cisplatin)	 and	 a	 taxane	 (paclitaxel	 or	 docetaxel).60–64 
Docetaxel	 is	 an	option	 in	patients	who	have	had	a	 significant	aller-
gic	reaction	to	paclitaxel	or	who	develop	early	sensory	neuropathy	as	
it	has	less	neurotoxicity,	but	it	 is	more	myelosuppressive	than	pacli-
taxel.60	The	SCOT-	ROC	(Scottish	Gynecological	Cancer	Trials	Group)	
study	 randomly	 assigned	 1077	women	with	 Stages	IC–IV	 epithelial	
ovarian	cancer	 to	carboplatin	paclitaxel	or	docetaxel.60	The	efficacy	
of	 docetaxel	was	 similar	 to	 paclitaxel.	 The	median	 progression-	free	
survival	was	15.1	versus	15.4	months.	The	MITO	2	trial	randomized	
over	800	patients	to	receive	either	carboplatin	and	liposomal	doxoru-
bicin	(PLD)	or	carboplatin	and	paclitaxel.	The	median	progression-	free	
survival	was	19.0	and	16.8	months	with	carboplatin/PLD	and	carbo-
platin/paclitaxel,	 respectively.65	 The	 median	 overall	 survival	 times	
were	 61.6	 and	 53.2	months	with	 carboplatin/PLD	 and	 carboplatin/
paclitaxel,	 respectively	 (hazard	 ratio	 [HR]	 0.89;	 95%	 CI	 0.72–1.12;	
P=0.32).	Carboplatin/PLD	produced	a	 similar	 response	 rate	but	dif-
ferent	toxicity	(less	neurotoxicity	and	alopecia	but	more	hematologic	
adverse	effects)	and	could	also	be	considered	as	an	option	in	patients	
where	paclitaxel	cannot	be	used.
Although	 intraperitoneal	 chemotherapy	 has	 been	 shown	 to	 be	
associated	with	improved	progression-	free	survival	and	overall	survival	
in	selected	patients	with	optimally	debulked	Stage	III	ovarian	cancer,	
it	is	not	widely	used	outside	the	USA	because	of	concerns	regarding	
increased	toxicity	and	catheter-	related	problems,	and	the	benefits	are	
still	debated.66–71	The	GOG	172	trial	compared	intravenous	paclitaxel	
plus	 cisplatin	with	 intravenous	paclitaxel	 plus	 intraperitoneal	 cispla-
tin	and	paclitaxel	 in	patients	with	Stage	III	ovarian	or	peritoneal	car-
cinoma,	with	no	residual	disease	greater	than	1	cm	in	diameter.68 Only 
42%	of	 patients	 in	 the	 intraperitoneal	 group	 completed	6	 cycles	 of	
the	assigned	therapy,	but	the	intraperitoneal	group	had	an	improve-
ment	in	progression-	free	survival	of	5.5	months	(23.8	vs	18.3	months;	
P=0.05)	and	an	improvement	in	overall	survival	of	15.9	months	(65.6	
vs	49.7	months;	P=0.03). Level of Evidence A
More	recently,	the	GOG	252	trial	reported	a	median	progression-	
free	 survival	 of	 approximately	 27–29	months	 in	 over	 1500	 patients	
with	 optimal	 Stage	II–III	 disease	 treated	with	 regimens	 consisting	 of	
different	combinations	of	intravenous	and	intraperitoneal	cisplatin,	car-
boplatin,	and	paclitaxel,	in	combination	with	bevacizumab.69	The	treat-
ment	arms	included	intravenous	carboplatin	AUC	6/intravenous	weekly	
paclitaxel	at	80	mg/m2;	intraperitoneal	carboplatin	AUC	6/intravenous	
weekly	paclitaxel	 at	80	mg/m;	 and	 intravenous	paclitaxel	 at	135	mg/
m2	on	day	one/intraperitoneal	cisplatin	at	75	mg/m2	on	day	two/intra-
peritoneal	paclitaxel	at	60	mg/m2	on	day	eight.	 In	addition,	each	arm	
received	intravenous	bevacizumab	at	15	mg/kg	with	cycles	2	through	
6	of	chemotherapy	and	then	alone	for	cycles	7	through	22.	The	median	
progression-	free	survival	by	intent-	to-	treat	analysis	was	24.9	(intrave-
nous	carboplatin),	27.3	 (intraperitoneal	carboplatin),	and	26.0	months	
(intraperitoneal	 cisplatin).	 An	 analysis	 limited	 to	 patients	 with	 opti-
mal	 Stage	 III	 tumors	 and	 no	 gross	 residual	 disease	 found	 a	 median	
progression-	free	survival	of	31–34	months	in	all	three	arms.	By	compar-
ison,	the	GOG	172	trial	comparing	intraperitoneal	and	intravenous	che-
motherapy	regimens	in	ovarian	cancer	had	a	median	progression-	free	
survival	of	23.8	months	with	 intraperitoneal	cisplatin	 (vs	18.3	months	
with	 intravenous)	with	an	 improvement	 in	overall	 survival	 in	 favor	of	
intraperitoneal	injection.68	In	addition,	the	median	progression-	free	sur-
vival	was	60	months	 in	the	patients	with	no	residual	disease	 in	GOG	
172.	Differences	in	the	cisplatin	arm	from	the	GOG	172	study	include	a	
dose	reduction	from	100	mg	to	75	mg	and	a	shorter	infusion	time	from	
24	hours	to	3	hours.68	If	intraperitoneal	treatment	is	used	it	would	be	
appropriate	to	follow	the	GOG	172	protocol	rather	than	the	modified	
protocol	with	a	lower	dose	of	cisplatin	accepting	the	increased	toxicity.
Combination	chemotherapy	with	either	intravenous	carboplatin	and	
paclitaxel	or	intraperitoneal	cisplatin	and	paclitaxel	(using	the	GOG	172	
protocol)	are	the	standard	treatment	options	for	patients	with	advanced	
disease,	 with	 evidence	 to	 support	 the	 addition	 of	 bevacizumab	 in	
selected	patients.	The	advantages	and	disadvantages	of	the	intravenous	
versus	intraperitoneal	routes	of	administration	of	these	drugs	should	be	
discussed	with	the	patient.	Intraperitoneal	chemotherapy	is	applicable	
only	to	patients	with	advanced	disease	who	have	had	optimal	debulking	
and	have	less	than	1	cm	residual	disease.	It	should	be	used	only	in	cen-
ters	that	have	experience	with	intraperitoneal	chemotherapy.
The	recommended	doses	and	schedule	for	intravenous	chemother-
apy	are:	carboplatin	(starting	dose	AUC	5–6),	and	paclitaxel	(175	mg/
m2),	every	3	weeks	for	6	cycles,51	or	the	dose-	dense	regimen	of	carbo-
platin	AUC	6	every	3	weeks	for	6	cycles	and	weekly	paclitaxel	80	mg/
m2.70	The	Japanese	GOG	 (JGOG)	 reported	 the	findings	of	 the	 latter	
regimen	 and	 showed	 improved	progression-	free	 survival	 and	overall	
T A B L E  3  Chemotherapy	for	advanced	epithelial	ovarian	cancer:	
recommended	regimens.a
Drugs 
Standard 
regimens Dose
Administration 
(h) Interval
No. of 
treatments
Carboplatin AUC=5–6 3 Every	3	wk 6–8 cycles
Paclitaxel 175 mg/m2
Carboplatin AUC=5–6 3 Every	3	wk 6 cycles
Paclitaxel 80 mg/m2 Every	
week
18	wk
Carboplatin AUC=5 3 Every	
week
6 cycles
Docetaxel 75 mg/m2 Every	3	wk
Cisplatin 75 mg/m2 3 Every	3	wk 6 cycles
Paclitaxel 135 mg/m2
Carboplatin	
(single 
agent)b
AUC=5 3 Every	3	wk 6	cycles,	
as 
tolerated
Abbreviation:	AUC,	area	under	the	curve	dose	by	the	methods	of	Calvert	
et	al.	75	and	Nagao	et	al.76
aReproduced	with	permission	from	Berek	et	al.,1 p.510.
bIn	patients	who	are	elderly,	frail,	or	poor	performance	status.
     |  67Berek eT AL.
survival.71	An	 Italian	 trial	 (MITO-	7)	 investigated	a	different	 schedule	
of	weekly	carboplatin	 (AUC	2	mg/mL	per	min)	plus	weekly	paclitaxel	
(60 mg/m2)	compared	with	carboplatin	(AUC	6	mg/mL	per	min,	admin-
istered	every	3	weeks)	and	paclitaxel	(175	mg/m2).72	The	weekly	regi-
men	did	not	significantly	improve	progression-	free	survival	compared	
with	 the	 conventional	 regimen	 (18.8	 vs	 16.5	months;	 P=0.18),	 but	
was	associated	with	better	quality	of	life	and	fewer	toxic	effects.	The	
results	of	the	ICON	8	trial	investigating	dose-	dense	paclitaxel	in	a	non-	
Japanese	population	have	been	recently	presented.73	Over	1500	pre-
dominantly	European	patients	were	randomized	to	receive	one	of	three	
regimens.	Arm	1:	carboplatin	AUC	5/6	and	paclitaxel	175	mg/m2	every	
3	weeks;	Arm	 2:	 carboplatin	AUC	 5/6	 every	 3	weeks	 and	 paclitaxel	
80 mg/m2	weekly;	and	Arm	3:	carboplatin	AUC	2	and	paclitaxel	80	mg/
m2	weekly.	All	patients	had	received	neoadjuvant	chemotherapy	with	
planned	interval	debulking	or	received	chemotherapy	after	initial	pri-
mary	cytoreductive	surgery.	There	was	no	benefit	found	for	the	dose-	
dense	regimens.	The	progression-	free	survival	was	24.4	months	with	
every	3-	week	dosing,	compared	with	24.9	and	25.3	months	in	arms	2	
and	3,	respectively.73	These	results	are	very	different	to	the	JGOG	trial	
and	 it	 seems	 that	 the	 likely	explanation	 is	due	 to	pharmacogenomic	
differences	between	these	two	ethnic	groups.74
The	recommended	doses	and	schedule	for	intraperitoneal	chemo-
therapy	are	paclitaxel	135	mg/m2	intravenously	on	day	one,	followed	
by	 cisplatin	 100	mg/m2	 intraperitoneally	 on	 day	 two,	 followed	 by	
paclitaxel	60	mg/m2	intraperitoneally	on	day	eight,	every	3	weeks	for	
6	 cycles,	 as	 tolerated.68,69	Many	 centers	modify	 the	 dose	 of	 cispla-
tin	to	75	mg/m2	 rather	than	100	mg/m2	 that	was	used	 in	GOG	172	
to	reduce	toxicity,	but	this	could	be	questioned	based	on	GOG	262	
results	 discussed	 above.69	Others	 substitute	 carboplatin	 (AUC	 5–6)	
for	 cisplatin	 in	 the	 regimen	 and	 the	 same	 caveats	 regarding	 lack	 of	
evidence	apply.69	The	role	of	intraperitoneal	carboplatin	is	being	eval-
uated	in	JGOG	and	the	results	should	be	available	in	the	near	future.
Bevacizumab	7.5–15	mg/kg	every	3	weeks	may	be	added	to	these	
regimens.77,78	Two	 studies	 have	 reported	 a	modest,	 but	 statistically	
significant	 increase	 in	progression-	free	 survival	 in	patients	 receiving	
maintenance	bevacizumab	following	carboplatin,	paclitaxel,	and	con-
current	bevacizumab.77,78	There	is	no	evidence	as	yet	to	demonstrate	
an	overall	survival	benefit,	but	a	subgroup	analysis	of	the	International	
Collaboration	 on	 Ovarian	 Neoplasms	 7	 (ICON7)	 trial	 reported	 an	
improved	median	survival	(30.3	vs	39.4	months)	in	patients	with	sub-
optimal	Stage	III	and	Stage	IV.77	The	role,	optimal	dose	(7.5	mg/kg	vs	
15	mg/kg),	timing	(primary	vs	recurrent	disease),	and	duration	of	treat-
ment	of	bevacizumab	are	still	debatable.
van	Driel	et	al.79	recently	reported	results	of	a	randomized	trial	in	
which	245	patients	with	Stage	 III	epithelial	ovarian	cancer	who	had	
received	3	 cycles	 of	 neoadjuvant	 chemotherapy	 underwent	 interval	
debulking	 surgery.	These	patients	were	 then	 randomized	 to	 receive	
either	 3	 more	 cycles	 of	 paclitaxel	 plus	 carboplatin	with	 or	without	
hyperthermic	 intraperitoneal	 chemotherapy	 (HIPEC).	 The	 addi-
tion	 of	 HIPEC	 to	 interval	 cytoreductive	 surgery	 resulted	 in	 longer	
recurrence-	free	 survival	 (14.2	 vs	 10.7	months)	 and	 overall	 survival	
(45.7	 vs	 33.9	months)	 and	 did	 not	 result	 in	 higher	 rates	 of	 adverse	
effects.	These	findings	are	provocative	and	raise	important	questions.	
Unfortunately,	 the	 study	 did	 not	 have	 an	 arm	 with	 intraperitoneal	
cisplatin	 alone	without	HIPEC,	 therefore	 it	 is	 not	 possible	 to	 know	
whether	the	improved	survival	was	due	to	the	addition	of	intraperito-
neal	cisplatin	alone	or	HIPEC.
In	 patients	 who	 may	 not	 tolerate	 combination	 chemotherapy	
because	of	medical	comorbidities	or	advanced	age,	single-	agent,	intra-
venously	administered	carboplatin	(AUC	5–6)	can	be	given.
For	 patients	who	 have	 a	 significant	 hypersensitivity	 reaction	 to	
paclitaxel,	an	alternative	active	drug	can	be	substituted	(e.g.	docetaxel,	
nanoparticle	paclitaxel,	or	liposomal	doxorubicin).	Carboplatin	hyper-
sensitivity	 is	very	 uncommon	 in	 the	 first-	line	 setting,	 but	 is	 seen	 in	
10%–20%	of	patients	with	recurrent	disease	who	have	multiple	lines	
of	platinum-	based	chemotherapy.80
In	patients	with	carboplatin	hypersensitivity,	desensitization	could	
be	attempted,	depending	on	the	severity	of	the	reaction,	or	alterna-
tively	cisplatin	(50–75	mg/m2)	may	be	an	option,	but	there	still	may	be	
a	risk	of	a	severe	allergic	reaction.
The	 treatment	 of	 all	 patients	 with	 advanced	 stage	 disease	 is	
approached	in	a	similar	manner,	with	dose	modifications	based	on	the	
toxicity	of	therapy.	Care	should	be	taken	when	considering	combina-
tion	chemotherapy	in	patients	with	a	very	poor	performance	status	or	
with	compromised	renal	function.
6.3 | Maintenance chemotherapy
Almost	80%	of	women	with	advanced-	stage	disease	who	respond	to	
first-	line	chemotherapy	 relapse.	There	have	been	several	 trials	con-
ducted	to	determine	 if	 there	 is	a	benefit	of	maintenance	therapy	 in	
these	 patients	 immediately	 following	 their	 primary	 treatment	 in	 an	
effort	to	decrease	the	relapse	rate.	These	were	all	negative	and	there	
is	no	evidence	to	support	maintenance	chemotherapy	after	comple-
tion	of	first-	line	therapy.
6.4 | PARP inhibitors
There	is	good	evidence	to	support	the	role	of	PARP	inhibitors	as	main-
tenance	therapy	following	response	to	chemotherapy	in	patients	with	
platinum-	sensitive	recurrent	ovarian	cancer,	as	well	as	monotherapy	
in	selected	patients	with	recurrent	ovarian	cancer.81–85	Patients	with	
BRCA	mutations	(both	germline	and	somatic)	have	the	greatest	ben-
efit,	but	a	subset	of	patients	with	tumors	with	homologous	recombi-
nation	deficiency	(HRD)	also	derive	benefit	from	treatment	with	PARP	
inhibitors;	the	ongoing	challenge	is	how	best	to	identify	these	patients.	
The	results	of	these	trials	are	summarized	in	Table	4.83–85	Readers	are	
directed	 to	 the	 chapter	 on	 targeted	 therapy	 in	 this	 Supplement	 by	
Basu	et	al.86	for	further	discussion	of	PARP	inhibitors.
7  | SECONDARY SURGERY
7.1 | Second- look laparotomy
A	second-	look	laparotomy	(or	laparoscopy)	was	previously	performed	
in	patients	who	have	no	clinical	evidence	of	disease	after	completion	
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of	 first-	line	 chemotherapy	 to	 determine	 response	 to	 treatment.	
Although	of	prognostic	value,	it	has	not	been	shown	to	influence	sur-
vival,	and	is	no	longer	recommended	as	part	of	the	standard	of	care.87 
Level of Evidence C
7.2 | Secondary cytoreduction
Secondary	cytoreduction	may	be	defined	as	an	attempt	at	cytoreduc-
tive	 surgery	 at	 some	 stage	 following	 completion	of	first-	line	 chemo-
therapy.	 Retrospective	 studies	 suggest	 that	 patients	 benefit	 if	 all	
macroscopic	 disease	 can	 be	 removed,	 which	 usually	means	 patients	
with	a	solitary	recurrence.	Patients	with	a	disease-	free	interval	longer	
than	12–24	months	and	those	with	only	1–2	sites	of	disease	appear	to	
derive	most	benefit.88,89	The	role	of	secondary	cytoreductive	surgery	
is	being	evaluated	 in	randomized	clinical	trials.	The	role	of	secondary	
debulking	 surgery	 has	 been	 addressed	 in	 the	DESKTOP	 III	 trial	 and	
the	results	recently	presented	by	Dubois	on	behalf	of	the	AGO.90 This 
study	included	patients	with	a	progression-	free	survival	of	greater	than	
6	months	 after	 first-	line	 chemotherapy	 and	who	were	 considered	 to	
be	good	candidates	for	surgery	based	on	a	positive	AGO	Study	Group	
score,	defined	as	an	ECOG	performance	status	score	of	zero,	ascites	of	
500	mL	or	less,	and	complete	resection	at	initial	surgery.	Du	Bois	et	al.90 
reported	that	the	median	progression-	free	survival	in	204	women	who	
met	 this	 criteria	 and	who	were	 randomized	 to	 undergo	 surgery	 fol-
lowed	by	chemotherapy	was	19.6	months,	compared	with	14	months	
in	203	women	who	were	randomized	to	receive	only	second-	line	chem-
otherapy.	The	primary	endpoint	of	the	study	is	overall	survival,	which	
will	only	be	available	in	a	few	years.	Level of Evidence C
8  | FOLLOW- UP FOR MALIGNANT 
EPITHELIAL TUMORS
There	is	no	evidence	to	show	that	 intensive	clinical	monitoring	dur-
ing	follow-	up	after	completion	of	primary	surgery	and	chemotherapy	
with	early	 initiation	of	chemotherapy	 in	asymptomatic	women	with	
recurrent	disease	improves	overall	survival	or	quality	of	life.	In	asymp-
tomatic	patients	with	CA125	progression	and	small	volume	disease	or	
no	radiological	evidence	of	recurrence,	it	is	appropriate	to	delay	start-
ing	chemotherapy.	However,	there	may	be	a	subset	of	patients	who	
are	suitable	for	secondary	debulking	surgery	at	the	time	of	recurrence.
The	objectives	of	follow-	up	include:
1.	 Early	 recognition	 and	 prompt	 management	 of	 treatment-related	
complications,	 including	 provision	 of	 psychological	 support.
2.	 Early	detection	of	symptoms	or	signs	of	recurrent	disease.
3.	 Collection	of	data	regarding	the	efficacy	of	any	treatment	and	the	
complications	associated	with	those	treatments	in	patients	treated	
in	clinical	trials.
4.	 Promotion	of	healthy	behavior,	including	screening	for	breast	can-
cer	in	patients	with	early	stage	disease,	and	screening	for	cervical	
cancer	in	patients	having	conservative	surgery.
There	are	no	evidence-	based	guidelines	 regarding	 the	appropriate	
follow-	up	schedule.	During	the	first	year	following	treatment,	patients	
are	 seen	every	3	months	with	a	gradual	 increase	 in	 intervals	 to	every	
4–6	months	 after	 2	years	 and	 then	 annually	 after	 the	 fifth	 year.	 At	
each	 follow-	up,	 the	patient	should	have	her	history	 retaken,	 including	
any	change	in	family	history	of	cancers	and	attention	to	any	symptoms	
that	could	suggest	recurrence;	a	physical	and	pelvic	examination	should	
be	performed.	This	 is	an	opportunity	 to	 refer	appropriate	patients	 for	
genetic	testing	if	it	was	not	done	at	diagnosis	or	during	treatment.	The	
CA125	 has	 traditionally	 been	 checked	 at	 regular	 intervals,	 but	 there	
has	been	debate	regarding	the	clinical	benefit	of	using	CA125	progres-
sion	alone	as	a	trigger	for	initiating	second-	line	chemotherapy.	A	large	
MRC	OV05-	EORTC	55955	study	 showed	 that	 treating	asymptomatic	
patients	with	recurrent	ovarian	cancer	with	chemotherapy	on	the	basis	
of	CA125	progression	alone	did	not	improve	survival	and	early	treatment	
in	asymptomatic	patients	had	a	negative	impact	on	quality	of	life.91 This 
study	has	generated	considerable	debate	 regarding	 the	use	of	CA125	
for	 follow-	up,	but	most	agree	that	 it	 is	 reasonable	not	to	 immediately	
initiate	treatment	unless	there	is	a	clear	clinical	indication	to	do	so.	The	
timing	of	treatment	should	be	based	on	symptoms	as	well	as	clinical	and	
radiological	findings.	Imaging	tests	such	as	ultrasonography	of	the	pelvis,	
CT,	MRI,	 and/or	positron	emission	 tomography	 (PET)	 scans	should	be	
performed	only	when	the	clinical	findings	or	the	tumor	markers	suggest	
possible recurrence.
There	appears	 to	be	no	benefit	 to	 initiating	chemotherapy	 in	an	
asymptomatic	 patient	 with	 recurrent	 disease	 based	 only	 on	 rising	
CA125	levels	in	the	absence	of	clinical	symptoms	or	radiological	evi-
dence	of	recurrence.	In	asymptomatic	patients	with	small	volume	dis-
ease	and	no	radiological	evidence	of	recurrence,	close	observation	is	a	
reasonable	option,	as	well	as	entry	into	an	appropriate	clinical	trial	or	
possibly	a	trial	of	tamoxifen	may	be	considered.
A	 Cochrane	 database	 systematic	 review	 of	 tamoxifen	 in	 unse-
lected	women	with	recurrent	ovarian	cancer	reported	a	10%	objective	
response	and	a	32%	disease	stabilization	rate.92	The	patients	treated	
were	heterogeneous	and	 included	asymptomatic	patients	with	rising	
CA125	levels,	and	symptomatic	patients	with	chemotherapy-	resistant	
T A B L E  4  Progression-	free	survival	endpoint	in	the	three	phase	
trials	of	maintenance	PARP	inhibitors.
Study
PARP inhibitor 
progression- 
free survival 
(months)
Placebo 
progression- 
free survival 
(months)
Hazard 
ratio
SOLO	283 19.1 5.5 0.3
NOVA84
gBRCA 21 5.5 0.27
Non-	BRCA 9.3 3.9 0.45
Non-	BRCA	HRD+ 12.9 3.8 0.38
ARIEL	3	85
gBRCA 16.6 5.4 0.23
HRD+	(includes	WT/
gBRCA)
13.6 5.4 0.32
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disease	who	had	been	heavily	pretreated	and	had	a	poor	performance	
status.	GOG	198	compared	tamoxifen	and	thalidomide	in	women	with	
recurrent	FIGO	Stage	III	or	IV	epithelial	ovarian,	tubal,	or	peritoneal	can-
cer	who	had	completed	first-	line	chemotherapy,	and	who	subsequently	
had	Gynecologic	Cancer	InterGroup	(GCIG)	documented	CA125	pro-
gression.	The	 study	 reported	 that	women	who	 received	 thalidomide	
had	a	31%	increased	risk	of	disease	progression	(HR	1.31),	compared	
with	those	who	were	given	tamoxifen.93	The	median	progression-	free	
survival	was	3.2	months	 in	the	thalidomide	group	versus	4.5	months	
in	the	tamoxifen	group.	This	suggests	that	tamoxifen	may	have	a	role	
in	 selected	 patients	with	 a	 rising	 CA125	 level,	 and	 the	 relationship	
between	estrogen	receptor	positivity	and	benefit	of	tamoxifen	in	this	
patient	population	is	being	evaluated	in	current	studies.
9  | CHEMOTHERAPY FOR RECURRENT 
EPITHELIAL MALIGNANCIES
The	majority	of	patients	who	present	with	advanced	epithelial	cancers	
of	 the	 ovary/fallopian	 tube/peritoneum	 will	 relapse	 with	 a	 median	
time	to	recurrence	of	16	months.	Patients	with	recurrent	ovarian	can-
cer	constitute	a	heterogeneous	group	with	a	variable	prognosis,	and	a	
variable	response	to	further	treatment.	The	most	widely	used	clinical	
surrogate	 for	predicting	response	to	subsequent	chemotherapy	and	
prognosis	 has	 been	 the	 progression-	free	 interval	 or	 the	 “platinum-	
free	interval,”	which	is	defined	as	the	time	from	cessation	of	primary	
platinum-	based	 chemotherapy	 to	 disease	 recurrence	 or	 progres-
sion.94,95	This	has	been	useful	to	define	specific	patient	populations,	
but	 it	has	a	number	of	 limitations	and	depends	on	how	patients	are	
followed.	In	particular,	it	depends	on	how	recurrence	is	detected	and	
defined.	Patients	with	a	treatment-	free	interval	of	less	than	6	months	
are	 classified	 as	 platinum	 resistant	 and	 generally	 treated	 with	
nonplatinum-	based	 chemotherapy,	 while	 those	 with	 a	 treatment-	
free	 interval	 of	more	 than	6	months	 are	 considered	 to	be	platinum	
sensitive	and	commonly	treated	with	platinum-	based	chemotherapy.	
Patients	who	progress	while	on	treatment	or	within	4	weeks	of	stop-
ping	chemotherapy	are	classified	as	platinum	refractory.94,95
There	 have	 been	 modifications	 to	 these	 definitions,	 and	 time	
to	 progression	 or	 recurrence	 rather	 than	 treatment-	free	 interval	 or	
platinum-	free	 interval	has	been	used	to	define	specific	patient	pop-
ulations.	There	has	been	significant	change	 in	practice	over	 the	 last	
20	years	and	patients	have	been	routinely	followed	with	regular	CA125	
testing	after	completion	of	chemotherapy.	For	example,	the	“platinum-	
resistant”	subgroup	may	 include	asymptomatic	patients	with	CA125	
progression	 alone	 at	 3	months	 post	 chemotherapy	 or	 radiological	
evidence	of	 recurrence	 as	well	 as	 those	who	 are	 symptomatic	with	
clinical	recurrence.	The	Fourth	Ovarian	Cancer	Consensus	Conference	
reached	agreement	that	distinct	patient	populations	should	be	based	
on	the	interval	from	last	platinum	therapy	and	the	time	to	progression.	
The	progression-	free	interval	is	defined	from	the	last	date	of	platinum	
dose	until	progressive	disease	is	documented.94,95
For	patients	whose	disease	 is	considered	platinum-	sensitive,	 the	
ICON	 4	 study	 showed	 advantage	 in	 terms	 of	 overall	 survival	 and	
progression-	free	survival	for	a	combination	of	carboplatin	and	pacli-
taxel	versus	single-	agent	carboplatin.96 Level of Evidence A
For	 patients	 with	 neurotoxicity,	 gemcitabine97 or liposomal 
doxorubicin98	may	be	 substituted	 for	paclitaxel.	A	 large	GCIG	study	
(CALYPSO)	compared	carboplatin	and	liposomal	doxorubicin	(CD)	with	
carboplatin	and	paclitaxel	(CP)	in	976	patients.99	The	CD	arm	had	sta-
tistically	superior	progression-	free	survival	compared	with	the	CP	arm,	
with	 a	median	 progression-	free	 survival	 of	 11.3	 versus	 9.4	months,	
respectively.	There	was	no	significant	difference	in	the	overall	survival	
between	 the	 treatment	groups.	Median	overall	 survival	was	33	ver-
sus	30.7	months	for	the	CP	and	CD	arms,	respectively.	The	CD	arm	
was	better	tolerated	with	less	severe	toxicities,	and	this	combination	
is	now	widely	used.	Level of Evidence A
There	is	evidence	that	the	addition	of	bevacizumab	to	the	regimen	
of	carboplatin	and	gemcitabine	improves	progression-	free	survival	com-
pared	with	carboplatin	and	gemcitabine	 in	platinum-	sensitive	disease.	
In	the	OCEANS	study,100	484	patients	with	platinum-	sensitive	disease	
were	randomly	assigned	to	carboplatin	(AUC	4	on	day	1)	and	gemcitabine	
1000 mg/m2	on	days	1	and	8)	with	or	without	bevacizumab	(15	mg/kg	
on	day	1)	with	every	21	days	cycles.	Bevacizumab	could	be	given	con-
currently	with	chemotherapy	for	a	maximum	of	10	cycles	followed	by	
bevacizumab	alone	until	progression	of	disease	or	toxicity.	The	addition	
of	bevacizumab	to	carboplatin	and	gemcitabine	resulted	in	an	improve-
ment	 in	 progression-	free	 survival	 (12	 vs	 8	months;	 HR	 0.48;	 95%	 CI	
0.39–0.61);	however,	there	was	no	difference	in	overall	survival	between	
the	two	arms.	Treatment	with	bevacizumab	was	associated	with	higher	
rates	of	serious	hypertension	(17%	vs	<1%),	proteinuria	grade	3	or	higher	
(9%	vs	1%),	and	noncentral	nervous	system	bleeding	(6%	vs	1%).100
For	patients	with	definite	platinum-	resistant	disease,	enrollment	on	
available	 clinical	 trials	or	 treatment	with	nonplatinum	chemotherapy	
should	be	considered.	There	are	a	number	of	chemotherapy	options	
including	liposomal	doxorubicin,101	topotecan,101	etoposide,102,103	and	
gemcitabine.104,105	The	 reported	 response	 rates	are	 low,	about	10%,	
with	a	median	time	to	progression	of	3–4	months	and	a	median	sur-
vival	of	9–12	months.	Over	the	last	5	years	there	have	been	a	number	
of	trials	carried	out	with	new	agents	in	patients	with	platinum-	resistant	
ovarian	 cancer,	 including	 epothilones,	 trabectedin106	 and	 perme-
trexed107	with	no	significant	increase	in	response	rates	or	progression-	
free	 survival.	 No	 new	 cytotoxic	 agent	 has	 been	 approved	 to	 treat	
recurrent	 ovarian	 cancer	 for	 many	 years.	 The	 role	 of	 angiogenesis	
inhibitors	in	platinum-	resistant	ovarian	cancer	is		discussed	below.
The	optimal	management	of	a	patient	with	platinum-	resistant	or	
refractory	 disease	 is	 complex	 and	 requires	 a	 careful	 assessment	 of	
the	 patient’s	 performance	 status,	 symptoms,	 and	 extent	 of	 disease.	
Attention	to	symptom	control	and	good	palliative	care	is	an	essential	
component	of	management.
With	very	few	exceptions,	recurrent	disease	is	not	curable	and	the	
aim	of	 treatment	 is	 to	maintain	quality	of	 life	and	palliate	symptoms	
particularly	in	patients	with	platinum-	resistant	ovarian	cancer.108 There 
are	many	potential	treatment	options,	including	chemotherapy,	angio-
genesis	 inhibitors,	 radiation	 therapy,	 or	 surgery	 in	 selected	 patients	
and	 inclusion	 in	 clinical	 trials.89	 There	 is	 a	 subset	 of	 patients	 who	
may	benefit	from	secondary	surgical	debulking,	but	they	constitute	a	
70  |     Berek eT AL.
minority.	The	role	of	secondary	surgical	debulking	is	being	addressed	in	
prospective	randomized	clinical	trials.	Level of Evidence C
9.1 | PARP inhibitors as monotherapy in patients 
with recurrent ovarian cancer
Olaparib	is	FDA	approved	for	the	treatment	of	patients	with	gBRCA-	
mutated	recurrent	ovarian	cancer	who	have	received	three	or	more	
prior	lines	of	chemotherapy.109,110	The	FDA	granted	approval	on	the	
basis	of	the	response	rate	in	a	single-	arm	study	of	olaparib	in	patients	
with	BRCA	mutations	and	with	a	wide	range	of	different	cancers.	The	
response	rate	was	34%	in	heavily	pretreated	BRCA-	positive	patients	
with	 platinum-	resistant	 recurrent	 ovarian	 cancer	 and	 the	 median	
progression-	free	survival	was	7.9	months.110
Rucaparib	 is	 also	 approved	 for	 treatment	 of	 BRCA-	mutation-	
associated	advanced	ovarian	cancer	after	completion	of	treatment	with	
two	or	more	 chemotherapy	 regimens	 regardless	of	whether	patients	
are	platinum-	sensitive	or	resistant.111	Rucaparib’s	approval	was	based	
primarily	 on	 efficacy	 data	 from	 106	 patients	 with	 BRCA-	associated	
recurrent	ovarian	 cancer	who	had	prior	 treatment	with	 two	or	more	
chemotherapy	regimens	and	safety	data	from	377	patients	with	ovarian	
cancer	treated	with	rucaparib	600	mg	orally	twice	daily	on	two	open-	
label,	single-	arm	trials.112	Investigator-	assessed	objective	response	rate	
was	54%	and	the	median	duration	of	response	was	9.2	months.112
10  | MANAGEMENT OF EPITHELIAL 
TUMORS OF LOW- GRADE 
SEROUS CANCERS
Low-	grade	 serous	 cancers	 (LGSCs)	 comprise	 5%	 to	 10%	 of	 serous	
ovarian	 cancers	 and	 up	 to	 8%	 of	 all	 ovarian	 cancers.113 They are 
typically	diagnosed	at	a	younger	age	than	in	women	with	high-	grade	
serous	ovarian	cancer	(HGSOC),	with	a	median	age	of	47–54	years	at	
diagnosis,	and	are	characterized	by	a	relatively	indolent	behavior	and	
resistance	to	cytotoxic	chemotherapy.114	In	contrast	to	HGSOC	they	
do	not	have	TP53	mutations,	but	may	have	KRAS or BRAF	mutations,	
and	activation	of	the	Ras-	Raf-	MEK-	ERK	signaling	pathway.114–116
Most	patients	with	low-	grade	serous	ovarian	cancer	(LGSOC)	have	
advanced-	stage	disease	at	initial	diagnosis	and	the	surgical	manage-
ment	is	similar	to	patients	with	high-	grade	cancers,	with	attempts	at	
total	resection	of	tumor—with	the	exception	of	fertility-	sparing	surgery	
in	younger	women	with	tumors	confined	to	the	ovary.	Neoadjuvant	
platinum-	based	chemotherapy	for	advanced-	stage	LGSOC	or	perito-
neum	was	associated	with	a	radiological	response	rate	of	4%,	which	
is	 much	 lower	 than	 response	 rates	 of	 up	 to	 80%	 in	 patients	 with	
HGSOC.117	Similarly,	the	response	rates	to	chemotherapy	have	been	
reported	to	be	low	in	a	number	of	studies	and	the	rate	was	only	3.7	
(4.9%	in	patients	with	platinum-	sensitive	disease	and	2.1%	in	those	
with	platinum-	resistant	disease)	in	a	report	of	patients	with	recurrent	
LGSC.114	 A	 recent	 retrospective,	 exploratory,	 case-	control	 analysis	
of	 over	 5000	 patients	 receiving	 adjuvant	 chemotherapy	 in	 clinical	
trials	 included	 145	 patients	 (2.8%)	 with	 LGSOC,	 of	 whom	 37	 had	
suboptimal	debulking	and	were	evaluable	for	response	evaluation.118 
The	response	rate	was	higher	than	other	studies	at	23.1%	in	this	small	
subset	of	patients	with	LGSOC	compared	with	90.1%	in	patients	with	
HGSOC.	 The	majority	 of	 patients	with	 LGSOC	will	 relapse	 despite	
treatment	and	have	a	relatively	long	survival	(median	overall	survival	
of	82	months).	These	patients	are	often	treated	with	multiple	agents	
over	many	years	for	recurrent	disease	with	variable	degrees	of	benefit	
and	the	impact	of	treatment	on	survival	is	unclear.118
10.1 | Management of low malignant potential 
(borderline) tumors
Compared	 with	 invasive	 epithelial	 cancers,	 borderline	 tumors	 tend	
to	 affect	 a	 younger	 population	 and	 constitute	 15%	 of	 all	 epithelial	
tumors	of	the	ovary.119	Nearly	75%	of	these	are	Stage	I	at	the	time	of	
diagnosis.	The	following	can	be	said	for	these	tumors120:
1.	 The	 diagnosis	 must	 be	 based	 on	 the	 pathology	 of	 the	
primary	tumor.
2.	 Extensive	sectioning	of	the	tumor	is	necessary	to	rule	out	invasive	
cancer.
3.	 The	prognosis	of	these	tumors	is	extremely	good,	with	a	10-year	
survival	of	about	95%.
4.	 Invasive	cancers	that	arise	in	borderline	tumors	are	often	indolent	and	
generally	have	a	low	response	to	platinum-based	chemotherapy.
5.	 Spontaneous	regression	of	peritoneal	implants	has	been	observed.
6.	 Early	 stage,	 serous	 histology,	 and	 younger	 age	 at	 diagnosis	 are	
associated	with	a	more	favorable	prognosis.
7.	 Although	gross	residual	disease	after	primary	laparotomy	is	associ-
ated	with	poorer	prognosis,	mortality	from	the	disease	remains	low.
8.	 Those	 patients	 who	 have	 invasive	 implants	 in	 the	 omentum	 or	
other	distant	sites	are	more	likely	to	recur	earlier.	The	role	of	cyto-
toxic	chemotherapy	is	questionable	as	the	response	rates	are	low.
The	 causes	 of	 death	 include	 complications	 of	 disease	 (e.g.	 small	
bowel	obstruction)	or	complications	of	 therapy,	and	only	 rarely	malig-
nant	 transformation.	 The	 mainstay	 of	 treatment	 is	 primary	 surgical	
staging	and	cytoreduction.	For	patients	with	Stage	I	disease	who	want	
to	 preserve	 fertility,	 conservative	 surgery	 with	 unilateral	 salpingo-	
oophorectomy	can	be	considered	after	intraoperative	inspection	of	the	
contralateral	ovary	to	exclude	involvement.121	For	patients	with	only	one	
ovary,	or	bilateral	cystic	ovaries,	a	partial	oophorectomy	or	cystectomy	
can	be	considered	for	fertility	preservation.	For	all	other	patients,	total	
hysterectomy	and	bilateral	 salpingo-	oophorectomy	are	 recommended,	
with	maximal	cytoreduction	if	the	disease	is	metastatic.
Patients	 with	 borderline	 tumors	 in	 all	 stages	 of	 disease	 should	
be	treated	with	surgery.	A	small	percentage	of	patients	with	invasive	
implants	 may	 respond	 to	 chemotherapy	 but	 the	 response	 to	 che-
motherapy	 is	 low.	Uncommonly,	some	patients	recur	early	and	have	
higher-	grade	invasive	cancers	and	may	benefit	from	chemotherapy.122
In	patients	with	late	recurrence	of	the	disease,	secondary	cytore-
duction	should	be	considered,	and	chemotherapy	given	only	if	invasive	
disease	is	present	histologically.
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Hormonal	therapy	has	been	reported	to	be	associated	with	clinical	
benefit	in	recurrent	and	metastatic	borderline	ovarian	tumors	as	well	
as	LGSC.	Hormonal	therapy	was	reported	to	have	a	response	rate	of	
9%	in	a	retrospective	analysis	of	64	patients	with	recurrent	LGSC.123 
In	26	patients	with	 LGSC	of	 the	ovary	or	peritoneum,	 adjuvant	hor-
mone	 therapy	 following	 debulking	 surgery	 was	 associated	 with	 a	
median	progression-	free	survival	of	22	months	and	recurrence	rate	of	
14.8%.124	In	this	small	study,	survival	of	the	patients	treated	with	adju-
vant	hormonal	 therapy	was	not	significantly	different	 to	an	age-	and	
stage-	matched	control	group	of	patients	with	LGSC	treated	with	sur-
gery	and	adjuvant	chemotherapy.	A	recent	retrospective	analysis	was	
reported	of	203	patients	with	LGSC	of	the	ovary	or	peritoneum	who	
received	 either	maintenance/adjuvant	 hormonal	 treatment	 or	 obser-
vation,	based	on	physician	discretion,	following	primary	cytoreductive	
surgery	and	platinum-	based	chemotherapy.125	Patients	who	received	
adjuvant	hormonal	therapy	had	significantly	longer	median	progression-	
free	survival	(64.9	vs	26.4	months)	compared	with	the	patients	in	the	
observation	group,	without	significant	prolongation	of	overall	survival	
(115.7	vs	102.7	months).	The	role	of	maintenance/adjuvant	hormonal	
therapy	in	patients	with	LGSC	will	soon	be	tested	in	a	large	NRG	trial.
Follow-	up	of	patients	with	no	evidence	of	disease	is	the	same	as	for	
those	with	malignant	epithelial	carcinomas,	but	at	less	frequent	inter-
vals.	If	the	contralateral	ovary	has	been	retained,	it	should	be	followed	
by	 transvaginal	 ultrasonography,	 at	 least	 on	 an	 annual	 basis.1,120,126 
Level of Evidence C
11  | MANAGEMENT OF GRANULOSA 
CELL TUMORS
Granulosa	 cell	 tumors	 account	 for	 about	 70%	 of	 sex-	cord	 stromal	
tumors	 and	3%–5%	of	 all	 ovarian	neoplasms.2	 There	are	 two	 types	
of	granulosa	cell	tumors:	the	juvenile	and	the	adult	types.	Because	of	
the	high	estrogen	production,	the	juvenile	type	typically	presents	with	
sexual	precocity,	while	 the	adult	 type	may	present	with	postmeno-
pausal	bleeding.	The	majority	of	patients	are	diagnosed	with	Stage	I	
tumors.	The	peak	incidence	is	in	the	first	postmenopausal	decade.2,127
Granulosa	cell	tumors	are	generally	indolent	(i.e.	with	a	tendency	
to	late	recurrence).	Stage	at	diagnosis	is	the	most	important	prognostic	
factor.	Other	prognostic	factors	include	age	at	diagnosis,	tumor	size,	
and	histologic	 features.	 If	metastatic,	 adequate	cytoreduction	 is	 the	
mainstay	of	treatment.	If	the	patient	is	young	and	the	disease	is	con-
fined	to	one	ovary,	conservative	surgery	should	be	performed.128,129
The	 infrequency	 of	 the	 disease,	 and	 its	 protracted	 course,	 has	
resulted	in	a	lack	of	prospective	studies.	There	is	no	evidence	that	adju-
vant	chemotherapy	or	radiotherapy	improves	the	results	of	surgery	alone	
for	Stage	I	disease.	The	value	of	postoperative	adjuvant	chemotherapy	
for	higher-	risk	Stage	I	disease	(tumor	size	>10	cm,	capsule	rupture,	high	
mitotic	count)	is	uncertain,	and	has	not	been	tested	in	randomized	stud-
ies.	Platinum-	based	chemotherapy	 is	used	for	patients	with	advanced	
or	recurrent	disease,	with	an	overall	response	rate	of	63%–80%.129–131
Follow-	up	 is	 clinical.	 For	 patients	with	 elevated	 levels	 of	 inhibin	
B	and/or	AMH	at	initial	diagnosis	of	granulosa	cell	tumors,	inhibin	B	
and/or	AMH	appear	to	be	reliable	markers	during	follow-	up	for	early	
detection	of	residual	or	recurrent	disease.132
There	is	no	evidence-	based	preference	for	inhibin	B	or	AMH	as	a	
tumor	marker.133	Serum	inhibin	is	a	useful	tumor	marker	in	postmeno-
pausal women. Level of Evidence C
12  | MANAGEMENT OF GERM 
CELL MALIGNANCIES
This	 group	 of	 ovarian	 tumors	 consists	 of	 a	 variety	 of	 histologically	
different	subtypes	that	are	all	derived	from	the	primitive	germ	cells	
of	 the	 embryonic	 gonad.	 Malignant	 germ	 cell	 tumors	 represent	 a	
relatively	small	proportion	of	all	ovarian	tumors.	Prior	to	advances	in	
chemotherapy,	the	prognosis	for	these	aggressive	tumors	was	poor.	
The	use	of	platinum-	based	chemotherapeutic	regimes	has	made	germ	
cell	malignancies	among	the	most	highly	curable	cancers.127
12.1 | Presentation
These	are	most	common	ovarian	tumors	in	the	second	and	third	decades	
of	 life.	They	are	frequently	diagnosed	by	finding	a	palpable	abdominal	
mass	in	a	young	woman	who	complains	of	abdominal	pain.	The	following	
are	the	symptoms	of	germ	cell	tumors	in	order	of	frequency127:
1.	 Acute	 abdominal	 pain.
2.	 Chronic	abdominal	pain.
3.	 Asymptomatic	abdominal	mass.
4.	 Abnormal	vaginal	bleeding.
5.	 Abdominal	distention.
12.2 | Histologic classification
The	 classification	 of	 germ	 cell	 tumors	 of	 the	 ovary	 is	 important	 to	
determine	prognosis	and	for	treatment	with	chemotherapy.	Germ	cell	
tumors	are	classified	as	follows2,127:
1. Dysgerminoma.
2. Embryonal carcinoma.
3.	 Polyembryoma.
4.	 Teratoma	 (immature;	mature;	mature	with	 carcinoma	 [squamous	
cell,	carcinoid,	neuroectodermal,	malignant	struma,	etc.]).
5.	 Extraembryonal	 differentiation	 (choriocarcinoma;	 endodermal	
sinus	tumor	[yolk	sac	tumor]).
12.3 | Diagnosis, staging, and surgical management
Ovarian	germ	cell	tumors	are	staged	similarly	to	epithelial	carcinomas,	
although	the	staging	system	used	for	male	germ	cell	tumors	is	prob-
ably	more	useful.	The	approach	to	treatment	is	based	on	the	principles	
of	management	of	metastatic	germ	cell	tumors	of	the	testis	(i.e.	low,	
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intermediate,	and	poor	risk).	Dysgerminoma	is	the	equivalent	of	semi-
noma	 in	 testicular	 cancer.134	 It	 is	 exquisitely	 sensitive	 to	 platinum-	
based	 chemotherapy	 and	 is	 radiosensitive.	 The	 cure	 rate	 is	 high	
irrespective	of	the	stage.	The	other	histologic	subtypes	are	equivalent	
to	nonseminomatous	testicular	cancer.	The	aggressiveness	of	the	dis-
ease	is	dependent	on	the	type,	the	most	aggressive	being	endodermal	
sinus	and	choriocarcinoma,	but	with	combination	chemotherapy,	they	
are highly curable.135–139
As	 chemotherapy	 can	 cure	 the	 majority	 of	 patients,	 even	 with	
advanced	disease,	conservative	surgery	is	standard	in	all	stages	of	all	
germ	cell	tumors.	Conservative	surgery	means	laparotomy	with	careful	
examination	 and	 biopsy	 of	 all	 suspicious	 areas,	with	 limited	 cytore-
duction,	 thereby	avoiding	major	morbidity.	The	uterus	and	 the	con-
tralateral	ovary	should	be	left	intact.	Wedge	biopsy	of	a	normal	ovary	
is	not	recommended	as	 it	defeats	the	purpose	of	conservative	ther-
apy	by	potentially	causing	 infertility.	Patients	with	advanced	disease	
may	benefit	 from	3	 to	4	cycles	of	neoadjuvant	chemotherapy	using	
BEP	(bleomycin,	etoposide,	cisplatin	[platinum])	regimen	with	preser-
vation	of	fertility.140	Patients	who	receive	conservative	surgery	with	
the	preservation	of	one	ovary	retain	acceptable	fertility	rates	despite	
adjuvant	treatment	with	chemotherapy.	There	has	been	no	report	of	
higher	adverse	obstetric	outcome	or	long-	term	unfavorable	sequelae	
in	the	offspring.141–144
Secondary	surgery	is	of	no	proven	benefit,	except	in	those	patients	
whose	tumor	was	not	completely	resected	at	the	initial	operation	and	
who	had	teratomatous	elements	in	their	primary	tumor.	Surgical	resec-
tion	of	residual	masses	may	be	beneficial	in	such	patients,	as	there	may	
be	mature	teratomatous	nodules	that	can	continue	to	increase	in	size	
(growing	teratoma	syndrome),	and	more	rarely	can	undergo	malignant	
transformation	over	time	to	an	 incurable	malignancy,	e.g.	squamous	
cell carcinoma.145
12.4 | Postoperative management and follow- up of 
dysgerminoma
Patients	with	Stage	IA	disease	may	be	observed	after	surgery.	A	small	
proportion	of	patients	may	 recur,	 but	 they	 can	be	 treated	 success-
fully	at	the	time	of	recurrence	with	a	high	rate	of	cure.	Patients	with	
disease	 beyond	 the	 ovary	 should	 receive	 adjuvant	 chemotherapy.	
Although	radiation	therapy	is	effective,	ovarian	failure	makes	it	unde-
sirable	for	patients	with	an	intact	ovary.
A	 follow-	up	 surveillance	 regime	 for	 patients	with	 Stage	1A	dys-
germinoma	is	outlined	in	Table	5.	This	schedule	is	based	on	the	expe-
rience	managing	 seminomas	 in	males	 and	 the	 reports	 by	 Patterson	
et	al.146	and	Dark	et	al.147	This	pragmatic	follow-	up	schedule	and	has	
not	been	tested	in	randomized	trials.
12.4.1 | Chemotherapy for dysgerminoma
Dysgerminoma	 is	 extremely	 sensitive	 to	 chemotherapy,	 and	 treat-
ment	with	 chemotherapy	 cures	 the	majority	 of	 patients,	 even	with	
advanced	disease.127,148	The	recommended	chemotherapy	regimen	is	
as	follows:
1.	 Etoposide	 (E)	 100	mg/m2	 IV	 per	 day	 for	 5	days	 every	 3	weeks	
for	 3	 cycles.
2.	 Cisplatin	(P)	20	mg/m2	 IV	per	day	for	5	days	every	3	weeks	for	3	
cycles.
3.	 Bleomycin	 (B)	 30	000	IU	 IV/IM	 on	 days	 1/8/15	 for	 12	weeks	
(Optional)	(Note:	bleomycin	is	dosed	in	International	Units).	If	bleo-
mycin	is	omitted,	then	4	cycles	of	EP	are	commonly	used.	Note	that	
various	schedules	of	bleomycin	have	been	used.
When	 there	 is	 bulky	 residual	 disease,	 it	 is	 common	 to	 give	 3–4	
courses	of	BEP	chemotherapy.148 Level of Evidence B
The	optimal	follow-	up	schedule	has	not	been	clinically	investigated	
in	ovarian	germ	cancers	and	the	frequency	of	visits	and	investigations	
is	 controversial.	 Patients	 who	 have	 Stage	 I	 tumors	 and	 are	 offered	
surveillance	need	to	be	seen	regularly	and	one	option	is	to	utilize	the	
follow-	up	regimen	presented	above.147	Patients	who	have	had	chemo-
therapy	have	a	lower	risk	of	recurrence	and	the	frequency	of	CT	scans	
can	be	 reduced,	which	 is	 similar	 to	 the	approach	 for	 testicular	germ	
cell	tumors.146	Each	follow-	up	visit	should	involve	taking	a	medical	his-
tory,	physical	examination,	and	tumor	marker	determination.	Although	
tumor	markers	 are	 important,	 radiological	 imaging	 is	 also	 pertinent,	
T A B L E  5  Follow-	up	regime	for	Stage	I	germ	cell	malignancies.a
Regimen Description
Surveillance Baseline	CT	chest,	abdomen,	and	pelvis,	if	
not	performed	preoperatively
Repeat	CT	or	MRI,	abdomen	and	pelvis	at	
3	months	after	surgery
Repeat	CT	or	MRI	abdomen	plus	pelvis	at	
12	months
Pelvic	ultrasound	alternate	visits	(not	
when	having	CT	scan)	for	2	years	if	
non-	dysgerminoma	and	for	3	years	if	
dysgerminoma
Chest	X-	ray	at	alternate	visits
Clinical	examination
1 year Monthly
2nd	year 2	monthly
3rd	year 3	monthly
4th	year 4	monthly
Years	5–10 6	monthly
Tumor	marker	followup Samples:	serum	AFP	and	hCG,	LDH	and	
CA	125	(regardless	of	initial	value)
0–6 mo 2	weekly
7–12 mo 4	weekly
12–24 mo 8	weekly
24–36 mo 12	weekly
36–48 mo 16	weekly
48+	mo 6	monthly	until	year	10
Abbreviations:	AFP,	alpha-	fetoprotein;	hCG,	human	chorionic	gonadotro-
pin;	LDH,	lactate	dehydrogenase.
aAdapted	from	Patterson	et	al.146
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especially	for	patients	whose	tumor	markers	were	not	raised	at	diag-
nosis.	CT	or	MRI	scans	should	be	performed	as	clinically	indicated.147
Patients	who	have	not	received	chemotherapy	should	be	followed	
closely.	Ninety	percent	of	relapses	in	these	patients	occur	within	the	
first	2	years.	At	 relapse,	with	 few	exceptions,	 these	patients	 can	be	
successfully	treated.147 Level of Evidence D
12.5 | Postoperative management and follow- 
up of nondysgerminoma germ cell malignancies
These	 tumors	 are	 highly	 curable	 with	 chemotherapy,	 even	 with	
advanced	disease.	Patients	with	Stage	IA	grade	1–2	immature	teratoma	
have	a	very	good	prognosis	and	should	be	only	observed	after	primary	
conservative	surgery.	Adjuvant	chemotherapy	does	not	appear	to	add	
any	 survival	 benefit	 in	 this	 subgroup	 of	 patients.	 All	 other	 patients	
with	nondysgerminomas,	and	higher-	stage	and	higher-	grade	immature	
teratomas,	should	receive	postoperative	adjuvant	chemotherapy.127
The	recommended	chemotherapy	regimen	 is	etoposide	100	mg/
m2	 per	 day	 for	 5	days	with	 cisplatin	 20	mg/m2	 per	 day	 for	 5	days,	
and	bleomycin	 at	 30	000	IU	 IM/IV	on	days	 1,	 8,	 and	15	 for	 a	 total	
of	12	weeks	of	treatment.	For	patients	with	good	prognosis	disease,	
3	cycles	of	BEP	are	recommended,	while	patients	with	intermediate/
poor	risk	disease	should	receive	4	cycles	of	BEP.127
Patients	who	relapse	after	BEP	may	still	attain	a	durable	remission	
and	cure	with	second-	line	chemotherapy	regimens	such	as	paclitaxel–
ifosfamide–cisplatin	 (TIP).137	 High-	dose	 chemotherapy	 and	 autolo-
gous	marrow	 rescue	may	 be	 considered	 in	 selected	 patients.	These	
patients	should	be	managed	in	specialized	units.
After	chemotherapy,	patients	with	metastatic	immature	teratomas	
can	 sometimes	 have	 residual	 masses,	which	 are	 composed	 entirely	
of	mature	elements.	These	masses	can	grow,	and	should	be	resected	
after	the	completion	of	chemotherapy.149 Level of Evidence B
All	 patients	 should	 have	 lactate	 dehydrogenase	 (LDH),	 alpha-	
fetoprotein	 (AFP),	 and	 human	 gonadotropin	 (beta	 hCG)	 to	 monitor	
response	to	treatment.	All	patients	treated	with	chemotherapy	should	
be	followed-	up	with	medical	history,	physical	examination,	and	appro-
priate	tumor	markers	in	the	same	way	as	dysgerminomas.	CT	or	MRI	
scans	should	be	performed	as	clinically	indicated.122
Relapses	 in	 patients	 usually	 occur	 within	 the	 first	 2	years	 after	
diagnosis127,137 Level of Evidence D
13  | SARCOMA OF THE OVARY
Ovarian	 sarcomas	 are	 rare	 and	 occur	 primarily	 in	 postmenopausal	
patients.127,150	 Nevertheless,	 accurate	 diagnosis	 and	 differentiation	
from	other	types	of	primary	ovarian	cancer	are	important,	as	the	prog-
nosis is generally poor.
There	 are	 two	 types	 of	 sarcoma.	 Malignant	 mixed	 Müllerian	
tumors	(MMMTs),	the	more	common	of	the	two,	are	biphasic	tumors	
composed	 of	 both	 carcinomatous	 and	 sarcomatous	 elements.150,151 
Most	authors	agree	that	most	MMMTs	are	monoclonal	in	origin	and	
should	be	thought	of	and	managed	as	a	high-	grade	epithelial	cancer.	
The	sarcomatous	component	is	derived	from	the	carcinoma	or	from	a	
stem	cell	that	undergoes	divergent	differentiation.	Thus,	ovarian	carci-
nosarcomas	are	best	regarded	as	metaplastic	carcinomas.
Pure	 sarcomas	are	very	 rare	and	should	be	 treated	according	 to	
the	specific	histologic	subtype.	These	rare	sarcomas	include	fibrosar-
comas,	 leiomyosarcomas,	 neurofibrosarcomas,	 rhabdomyosarcomas,	
chondrosarcomas,	 angiosarcomas,	 and	 liposarcomas.	 Their	 manage-
ment	is	not	discussed	here.
Patients	 with	 early	 stage	 MMMTs	 have	 a	 better	 outcome	 than	
those	with	advanced	stage	disease,	but	the	overall	prognosis	is	poor.	
They	should	be	managed	similarly	to	high-	grade	pelvic	serous	cancers.	
Their	rarity	prohibits	any	prospective	randomized	trials.
The	principles	of	surgical	management	of	ovarian	MMMTS	are	the	
same	 as	 for	 high-	grade	 pelvic	 serous	 cancers.127	 Following	 surgery,	
patients	 should	 receive	platinum-	based	chemotherapy.127,147,148 The 
follow-	up	 schedule	 is	 as	 recommended	 for	 epithelial	 malignancies.	
Level of Evidence C
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